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ABSTRACT

CHROMODOMAIN HELICASE DNA BINDING PROTEIN 1 (CHD1) IS REQUIRED
FOR OROFACIAL DEVELOPMENT IN XENOPUS

By Brent Hardin Wyatt, PhD.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2018

Major Director: Amanda Dickinson, PhD.
Associate Professor, Department of Biology

Abnormalities affecting orofacial development are some of the most common,
expensive, and devastating birth defects. Children born with such defects may experience
difficulties with eating, breathing, and speech and in addition, these defects often require
multiple surgeries to correct them. Therefore, it is critical to understand how the orofacial
region develops in order to better treat and prevent these types of birth defects. Xenopus

laevis has emerged as a strong model in which to examine orofacial development and
was utilized here to investigate the cellular and molecular mechanisms underlying the
complex development of the orofacial region. Retinoic acid is one signal involved in
orchestrating orofacial development and accomplishes this in part by regulating the
nucleosome structure of target genes. The work presented here characterizes the role of
an ATP-dependent chromatin remodeler, chromodomain helicase DNA binding protein 1
(Chd1), in orofacial development in X. laevis. The spatial expression of Chd1 supports its
role in orofacial development and reduced expression of Chd1 resulted in abnormal facial
development. Closer examination of Chd1 morphant embryos revealed that Chd1 is
required for the expression of important neural crest and cartilage genes that are
necessary for proper development of the face. In addition, there was an increase in
apoptosis in regions consistent with migrating neural crest and neural crest derived
structures. As a consequence, many of the facial cartilages do not form properly in
morphant embryos resulting in a smaller face. Further, this work presents evidence that
Chd1 may cooperate with retinoic acid to regulate orofacial development in X. laevis.

CHAPTER 1 THE ROLE OF CHROMODOMAIN HELICASE DNA BINDING PROTEIN
1 (CHD1) IN OROFACIAL DEVELOPMENT

The face is one of the most important features of humans and is necessary for
eating, breathing, communication, and social recognition. Therefore, birth defects
affecting the face can be devastating. In addition, such defects can also affect the
psychological development of the children born with them (Centers for Disease Control
and Prevention, 2018). Some facial defects can be surgically corrected, however, such
procedures can be difficult, and usually requires a team of medical professionals and
multiple surgeries, resulting in thousands of dollars in healthcare costs. Therefore, it is
important to understand how the orofacial region develops to help prevent these defects
from occurring.
In this chapter, X. laevis was utilized to investigate Chromodomain helicase DNA
binding protein 1 (Chd1), a chromatin remodeler that is critical for early development and
has been difficult to study in an embryo due to the severity of knockout of this gene
(Guzman-Ayala et al., 2015). Therefore, the expression of Chd1 was reduced with
titratable antisense oligos in Xenopus laevis embryos to characterize the role of Chd1 in
orofacial development. This is the first study to elucidate the role of Chd1 during the
development of this region. Further, this chapter also presents findings that suggest the
possibility of a cooperation between Chd1 and retinoic acid.

1

INTRODUCTION

Midface and palate development

The developing orofacial region is carefully crafted by the growth and merging of
facial prominences through an orchestration of apoptosis, cell division, and cell
movements. Such orchestration is regulated by a complex network of signals,
transcription factors, and epigenetic factors. In addition, both genetic and environmental
factors can impact orofacial development (Chai and Maxson, 2006; Cordero et al., 2011;
Jiang et al., 2006; Szabo-Rogers et al., 2010). The orofacial region and surrounding
midface tissues are composed of the mouth, primary palate, upper lip, philtrum, nose,
and the area between the eyes (Sperber et al., 2010). These structures are created by
the growth and fusion of the facial prominences, which include the frontonasal
prominence, the paired medial nasal prominences, the paired lateral nasal prominences,
and the paired maxillary prominences.
This process of the growth and fusion of the facial prominences begins with the
thickening of the ectoderm of the frontonasal prominence to form the nasal placodes. The
nasal placodes continue to develop and form the nasal pits and in addition, the medial
and lateral nasal prominences arise from cell proliferation around the nasal placodes.
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Next, the maxillary prominences push the nasal pits and the medial nasal prominences
toward the midline. Following this process, the upper lip forms from the fusion of the
maxillary and medial nasal prominences. The distal part of the medial nasal prominence
forms the intermaxillary segment, which grows into the oral cavity to form the primary
palate. The maxillary prominences will fuse with the primary palate to form the secondary
palate (Jiang et al., 2006; Suzuki et al., 2016). Defects in the growth or fusion of these
prominences can result in orofacial clefts, midface hypoplasia, or hypertelorism (Suzuki
et al., 2016). In non-amniotes such as Xenopus and zebrafish, the fusion of these
prominences appears to occur directly without a midline epithelial seam that occurs in
amniotes (Dudas et al., 2007; Iseki, 2011; Kennedy and Dickinson, 2012; Swartz et al.,
2011). Additionally, amniotes form a secondary palate that separates the oral and nasal
cavities and fuses with the primary palate, while, non-amniotes do not form a secondary
palate, but instead, the primary palate grows posteriorly (Ferguson, 1988). Regardless of
these differences between amniotes and non-amniotes, the signaling processes involved
in directing the growth and merging of the facial prominences are well conserved (SzaboRogers et al., 2010).

Using Xenopus to investigate orofacial development

X. laevis has proven to be a valuable tool to study the cellular and molecular
mechanisms regulating orofacial development (Dickinson, 2016). X. laevis produces
large clutches of embryos that develop ex-utero, thus, making the face easily visualized
throughout development. Further, X. laevis embryos do not display head flexure that can
make visualization of the orofacial region difficult in other models, such as zebrafish,
3

mouse, and chick embryos. In addition, orofacial development is well conserved in this
species (Dickinson and Sive, 2007). X. laevis has long been used in classical
embryological studies and the ease of chemical treatments make Xenopus a useful model
to study chemical genetics. Further, many modern techniques are applicable in Xenopus.
For instance, molecular loss and gain of function experiments are routine and face
transplants are amenable in X. laevis (Dickinson, 2016; Dickinson and Sive, 2009; Jacox
et al., 2014).

Retinoic acid signaling

The development of the facial prominences is guided in part by retinoic acid
signaling (Mark et al., 2004), which regulates proliferation, differentiation, and apoptosis
during embryogenesis (Finnell et al., 2004). Retinoic acid is important for the development
of the neural crest cells (Brickell and Thorogood, 1997), which contribute to the
establishment of the facial primordia. In addition, retinoic acid is necessary for the
development of the neural crest derived branchial arches that give rise to head structures
(Mark et al., 2004). Over- or under-exposure to retinoic acid during fetal development can
disrupt closure of the neural tube and lead to developmental defects, such as orofacial
clefts. During palatogenesis, excess retinoic acid can disturb palatal shelf outgrowth,
palatal shelf elevation, and shelf fusion, by interfering with cell proliferation and growth
factors (Ackermans et al., 2011). When chick embryos are exposed to excess retinoic
acid during early stages of development, the upper beak does not form, while the lower
beak develops normally (Wedden et al., 1988). Further, the lower jaw forms abnormally
into upper jaw-like structures in mice exposed to excess retinoic acid at E8.5, when neural
4

crest cells are migrating (Abe et al., 2008). The development of neural crest derived
craniofacial skeletal elements are also disrupted in mice with compound null mutations of
retinoic acid receptors (Lohnes et al., 1994) and ablation of retinoic acid receptors in
neural crest cells in mice leads to severe defects in derivatives of branchial arch structures
(Dupe and Pellerin, 2009).
Retinoic acid is derived from vitamin A via two oxidation reactions. In the first
reaction, alcohol and retinol dehydrogenases oxidize retinol to retinaldehyde. In the
second reaction, retinaldehyde dehydrogenase converts retinaldehyde to retinoic acid. In
the cell, retinoic acid binds to receptors found in the nucleus to regulate transcription of
target genes. These receptors include RARs and RXRs that usually bind as a heterodimer
to DNA binding sites called retinoic acid response elements (RAREs) that are found in
the regulatory region of target genes. These receptors cooperate with co-repressors and
co-activators to regulate the genes targeted by retinoic acid (Niederreither and Dolle,
2008; Rhinn and Dolle, 2012).
When retinoic acid receptors are bound to RAREs in the absence of retinoic acid,
the receptors recruit corepressors including nuclear receptor co-repressor (NCoR) and
silencing mediator for retinoid or thyroid hormone receptors (SMRT). The corepressors
help recruit histone modifiers and chromatin remodelers to stabilize the nucleosome
structure so that DNA is inaccessible to the transcriptional machinery (Fig. 1.1A). One
such category of a histone modifier recruited by the corepressors are histone
deacetyltransferases (HDACs) (Niederreither and Dolle, 2008). HDACs remove acetyl
groups from histone proteins resulting in an increase in the positive change of histone
tails and encourage stronger interaction between the histones and DNA (Haberland et
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al., 2009b). Another category of histone modifiers recruited by the corepressors are
histone methyltransferases that methylate lysine residues of histone tails that are
associated with transcriptional repression, including H3K9, H3K27, and H4K20. In
addition, ATP dependent chromatin remodelers, such as members of the SMARCA family
and SWI/SNF complexes, are recruited to further aid in stabilizing the nucleosome
structure (Bastien and Rochette-Egly, 2004; Niederreither and Dolle, 2008; Rosenfeld et
al., 2006).
When retinoic acid binds to the receptors, the receptors undergo a conformational
change that releases the corepressors and creates a binding surface for coactivators,
including members of the SRC/p160 family, p300/CBP, and CARM-1. These coactivators
destabilize the nucleosome structure also via histone modification and recruitment of
ATP-dependent chromatin remodelers (Fig. 1.1B). One such modification is histone
acetylation (Bastien and Rochette-Egly, 2004; Niederreither and Dolle, 2008; Rosenfeld
et al., 2006), which adds acetyl groups to lysine residues of histone tails and neutralizes
the positive charge of these histone tails. This weakens the interaction between histones
and DNA (Haberland et al., 2009b). Additionally, histone methyltransferases modify
methylation of lysine residues on the histone tails to remove methylation that is associated
with transcriptional repression and methylate lysine residues that are associated with
transcriptional activation, including H3K4. The coactivators can also interact with the
basal transcriptional machinery. (Niederreither and Dolle, 2008; Rosenfeld et al., 2006).
Retinoic acid targets numerous genes including Hox genes, signaling factors and
hormones, receptors, enzymes, and genes involved in the retinoid pathway (Rhinn and
Dolle, 2012).
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Retinoic acid is important for midface and palate development in X. laevis
(Kennedy and Dickinson, 2012). More specifically, decreased retinoic acid signaling
during a specific window of orofacial development results in a median cleft in X. laevis
and mice (Dupe and Pellerin, 2009; Kennedy and Dickinson, 2012). An expression and
pathway analysis was utilized to gain insight into how retinoic acid regulates midface
development (Kennedy and Dickinson, 2012; Wahl, in prep). In this analysis, embryos
were exposed to a RAR inhibitor from stage 24-30 (26-37.5 hpf). After exposure to the
RAR inhibitor, the orofacial region of the embryos was dissected and this was followed
by isolation of RNA from these orofacial tissues. A microarray analysis was utilized to
examine the isolated RNA to identify targets of retinoic acid. One class of genes identified
in this work were transcriptional regulators including histone and chromatin modifiers.
This prompted the hypothesis that retinoic acid signaling is required for the expression of
the transcriptional machinery necessary to perpetuate this signal.

Chromodomain helicase DNA binding protein 1

One gene altered in the expression analysis that may represent a novel regulator
of orofacial development was chromodomain helicase DNA binding protein 1, or Chd1.
This gene encodes a member of the chromodomain helicase DNA binding protein family
and is conserved in metazoans from yeast to humans. There are three domains important
for Chd1 function. 1) A pair of N-terminally located chromodomains that function to bind
to nucleosomes, 2) a centrally located ATP dependent SNF2-like helicase domain that
helps to disrupt the interaction between DNA and histone proteins, and 3) a C-terminally
located DNA binding domain that binds preferentially to A+T rich regions. Together, these
7

domains function to modify chromatin structure to regulate transcription (Hall and
Georgel, 2007; Marfella and Imbalzano, 2007).
Most often, Chd1 is associated with active transcription. For example, Chd1 binds
to methylated H3K4, which is associated with promoters of active genes in mammals and
Drosophila (Eissenberg et al., 2007; Flanagan et al., 2005; Sims et al., 2005). Additionally,
Chd1 localizes to the interband and puff regions of Drosophila polytene chromosomes,
which are associated with extended chromatin and high transcriptional activity
respectively (Stokes et al., 1996). Further, Chd1 interacts with Rtf1, a subunit of the
polymerase association factor (PAF) complex, and Spt5, a component of DRB-sensitivity
inducing factor (DSIF) in yeast, both of which are integral for transcriptional elongation
(Simic et al., 2003). In addition, Chd1 also interacts with proteins that function to rearrange
nucleosomes. One of which is Pob3, a component of the FACT (facilitates chromatin
transcription) complex in yeast, and the Pob3 homologue, SSRP1, in mammalian nuclei
and drosophila polytene chromosomes (Kelley et al., 1999; Simic et al., 2003). Overall,
the role of Chd1 in active transcription is an important part of metazoan development.
On the cellular level, Chd1 is necessary for open chromatin and stem cell
pluripotency in mouse embryonic stem cells (Gaspar-Maia et al., 2009). With the
complete loss of Chd1, mouse embryos arrest developmentally prior to gastrulation.
Further investigation into the cause of the developmental arrest revealed that Chd1 is
necessary to facilitate a high transcriptional output. Without this high transcriptional
output, the embryo is not capable of generating the cell population that is necessary to
progress through the complex morphogenesis and rapid growth of this early
developmental phase (Guzman-Ayala et al., 2015). Furthermore, Chd1 is needed to
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activate hmgpi and klf5 at zygotic gene activation (ZGA) to control initiation of cell fate
specification (Suzuki et al., 2015). An investigation using a conditional knockout of Chd1
specifically in endothelial cells in mouse embryos revealed that Chd1 is important for
definitive erythropoiesis. Without Chd1 in endothelial cells, mouse embryos die due to
anemia early during development (Koh et al., 2015). While these studies elegantly reveal
a critical role for Chd1 during embryonic development in mammals, additional studies are
required to better understand the later developmental roles of Chd1, specifically during
orofacial development.

Epigenetics modifiers are important for craniofacial development

While there is little information about a potential role for Chd1 during craniofacial
development, other epigenetic modifiers are important for craniofacial development
(summarized in table 1.1). This includes other members of the CHD family. One such
example is Chd7, which is associated with CHARGE syndrome, and can include
craniofacial defects such as a square-shaped face, a broad nasal bridge, a small mouth,
and cleft lip and/or cleft palate (Zentner et al., 2010). Using cell culture and Xenopus
embryos, it was shown that Chd7 is important for neural crest specification and migration
(Bajpai et al., 2010). Furthermore, this isn’t the only member of the CHD protein family
associated with craniofacial development. Mutations in Chd8 can result in macrocephaly,
hypertelorism, down-slanted palpebral fissures, broad nose, pointed chin, and a broad
forehead with prominent supraorbital ridge in humans (Bernier et al., 2014).
Macrocephaly was also observed in Chd8+/- mouse embryos, and this work revealed that
Chd8 regulates cell cycle and histone modification (Platt et al., 2017). Together this data
9

highlights an important role for CHD proteins in craniofacial development. In addition,
there is also a large body of data now emerging that epigenetic modifiers in general are
instrumental in coordinating the complex development of neural crest and the embryonic
face.
These epigenetic modifiers include other chromatin remodelers such as ATRX.
Mutations in ATRX can lead to telecanthus, midface hypoplasia, and a tented upper lip
(Gibbons and Higgs, 2000). In addition, mutations in Williams syndrome transcription
factor (WSTF), a subunit found in WINAC, WICH, and BWICH chromatin remodelers, is
associated with Williams-Beuren syndrome (Lu et al., 1998). These mutations can lead
to a broad forehead, flat nasal bridge, a wide mouth, malar flattening, and full cheeks
(Burn, 1986; Metcalfe, 1999). Another example is the chromatin organizer CFDP1. It has
been suggested that mutations in CFDP1 may be associated with microcephaly (Messina
et al., 2017). Certainly, chromatin modifiers are not the only category of epigenetic
modifiers that are important for craniofacial development.
Another category is

histone modifiers, such

as HDACs and histone

methyltransferases. Mutations in Hdac8 can lead to Cornelia De Lange syndrome 5
(Kaiser et al., 2014), which is characterized by dysmorphic facial features including
microcephaly, flat midface, downturned corners of the mouth, and micrognathia (Boyle et
al., 2015). Additional investigations of HDACs, including Hdac1 and Hdac4, have
demonstrated that these proteins are important for formation of the craniofacial cartilage
and bone in animal models (DeLaurier et al., 2012; Haberland et al., 2009b; Pillai et al.,
2004). Histone methyltransferases and polycomb repressive complexes that have histone
methyltransferase activity are also important for the development of the craniofacial
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cartilage and bone. For example, the histone methyltransferase, Phf8, is necessary for
proper jaw development in zebrafish (Qi et al., 2010). Further, Ezh2, a member of the
polycomb repressive complex 2, is important for neural crest positional identity (Minoux
et al., 2017) and cartilage and bone formation in mice (Schwarz et al., 2014). In humans,
mutations in Ezh2 are associated with Weaver syndrome, which can be characterized by
macrocephaly and hypertelorism (Gibson et al., 2012). Another polycomb repressive
complex member, Ring1b/Rnf2, is necessary for the development of the craniofacial
cartilage, bone, and musculature in zebrafish (van der Velden et al., 2013).
Finally, another factor involved are proteins such as Rai1, which is a protein that
interacts with chromatin and is thought to function as a histone code reader (Darvekar et
al., 2013). Rai1 has been associated with Smith-magenis syndrome (Carmona-Mora et
al., 2010), which can lead to brachycephaly, midface hypoplasia, bow shaped mouth, and
prognathism (De Leersnyder, 2013). Investigations into the role of Rai1 during
development in X. laevis revealed that loss of Rai1 function results in defects in neural
crest migration and development of the facial cartilage (Tahir et al., 2014). Together,
these studies highlight the importance of epigenetic modifiers in craniofacial
development.
Given the complexity of craniofacial development, it was predicted that
transcription and epigenetic factors are specifically required for the precise interpretation
of signals and the coordination of gene expression necessary for the formation of this
structure. Therefore, the purpose of this study is to test the effects of perturbing epigenetic
regulators, in particular Chd1, on orofacial development, and further, to determine
whether Chd1 cooperates with retinoic acid signaling during midface development.
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METHODS

1. Animals

Xenopus laevis embryos were obtained using standard procedures (Sive et al.,
2000) approved by the VCU Institutional Animal Care and Use Committee (IACUC
protocol number AD20261). Embryos were staged according to Nieuwkoop and Faber
(Nieuwkoop and Faber, 1994).

2. Table of Genes

The genes included in this table were identified from an expression analysis
conducted on embryos treated with the retinoic acid receptor inhibitor BMS-453. The
embryos were treated with 10µM BMS-453 from stages 24-30 (26-35 hpf). Following
treatment, the orofacial region was dissected from these embryos for RNA isolation and
microarray analysis (Kennedy and Dickinson, 2012) (Wahl in prep). The genes that were
decreased by 1.5 fold or greater in this expression analysis were analyzed manually. The
accession numbers were used to search the NCBI database to identify the gene name.
Then, the gene name was used to search the GeneCards human gene database
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(http://www.genecards.org) to identify the function of the protein encoded by these genes.
Any genes that were identified to play a role in chromatin regulation, histone modification,
transcriptional initiation, or transcriptional elongation were included in the table.

3. Chemical Treatments

a. Transcriptional regulation inhibitors
Stock solutions of the transcriptional elongation inhibitor leflunomide (Sigma
L5025), 100uM in DMSO) and the histone deacetylase inhibitor trichostatin A (Sigma
T8552, 100mM in DMSO) were created. The stock solution of trichostatin A was further
diluted to a concentration of 0.1mM in DMSO. Treatments were performed in 2ml of 0.1X
modified Barth’s saline (MBS) with 1% DMSO in a 12-well plate. 10 embryos per well
were incubated in 200µM leflunomide or 0.1µM trichostatin A from stage 24 (26-27.5 hpf)
to stage 29-30 (35-37.5 hpf) at 15°C. Control treated embryos were raised in 0.1X
Modified Barth’s saline (MBS) with 1% DMSO from stage 24 (26-27.5 hpf) to stage 29-30
(35-37.5 hpf) at 15°C. Embryos were removed from the treatment at stage 29-30 (35-37.5
hpf) and raised to stage 43 (87-92 hpf) in 0.1X MBS, at which point they were fixed in 4%
paraformaldehyde (PFA) overnight at 4°C. This was followed by three washes in
phosphate buffered saline with tween-20 (PBT).

b. RAR Inhibitor
A stock solution of an RAR inhibitor (BMS-453, Tocris 3409, 10mM in DMSO) was
created. This stock solution was further diluted to a concentration of 1mM in DMSO.
Treatments were performed in 4ml of 0.1X MBS with 1% DMSO in a 6-well plate. 10
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embryos per well were bathed in 1µM BMS-453 from the 2-cell stage (1.5-2 hpf) to stage
43 (87-92 hpf). Control treated embryos were raised in 4ml of 0.1X MBS with 1% DMSO
from the 2-cell stage (1.5-2 hpf) to stage 43 (87-92 hpf). The media was refreshed each
day during treatment. At the end of treatment, embryos were fixed in 4% PFA overnight
at 4°C. This was followed by three washes in PBT.

c. RAR Agonist
A stock solution of the RAR agonist (TTNPB, Tocris 0761, 10mM in DMSO) was
created. Treatments were performed in 4ml of 0.1X MBS with 1% DMSO in a 6-well plate.
10 embryos per well were bathed in 2.5µM TTNP at stage 23 (25-26.5 hpf) for four hours
at room temperature. Control treated embryos were bathed in 4ml of 0.1X MBS with 1%
DMSO at stage 23 (25-26.5 hpf) for four hours at room temperature. At the end of
treatment, embryos were placed in 1ml of Trizol for RNA isolation as described in 6b.

4. Imaging

a. Whole embryos
Whole embryos were imaged in a petri dish containing PBT using a dark
background. Embryos were imaged using a Zeiss Discovery V8 stereoscope fitted with a
Zeiss Axiocam MRc camera.

b. Faces
To obtain images of the face, the head was removed from the body of fixed
embryos with a scalpel. This was done by first making a cut through the body at the
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posterior end of the gut to remove internal pressure while making the second cut to
remove the head. A second cut at the anterior end of the gut was used to remove the
head. The heads were positioned in dishes lined with clay and filled with PBT. A glass
pipette tool was used to create a depression in the clay in which to place the embryo
head. This glass pipette tool was created by first heating the very tip of the pipette over a
flame. As the glass soften and began to curve, the pipette was removed from the flame
to create a roughly 90° bend. Two pairs of forceps were used to push the clay around the
head to hold it in place. Embryos were imaged using a Zeiss Discovery V8 stereoscope
fitted with a Zeiss Axiocam MRc camera.

c. In situ
Fixed embryos were placed through a glycerol series. Beginning in PBT, the
embryos were incubated in 50% glycerol in PBT, then 75% glycerol in PBT, and finally
100% glycerol. The embryos were incubated at each step of the series until they sank to
the bottom of the tube. Whole embryos were imaged in a petri dish containing 100%
glycerol on a white background as described in section 4A. To obtain images of the face,
the head was removed in PBT as described in section 4B. Next, the heads were placed
through the same glycerol series as whole embryos. Finally images were taken as
described in section 4B in a dish lined with clay and filled with glycerol. The exception to
this is the image of the face at stage 40 (66-76 hpf). These embryos were sectioned using
a Leica VT1000P vibrotome to section heads mounted in low melt agarose.
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5. Computational analysis of Chd1 gene and protein sequences

The full length sequences for chd1 for Homo sapiens (AF006513.1), Mus musculus
(NM_007690.3),

Xenopus

(XM_018244340.1),
(NM_057849.5),

Danio

laevis
rerio

Caenorhabditis

L

(XM_018264496.1),

(NM_001128298.2),
elegans

Xenopus

Drosophila

(NM_059593.6),

and

laevis

S

melanogaster
Saccharomyces

cerevisiae (NM_001179054.1) were retrieved from NCBI. The sequences were aligned
with Clustal Omega to determine the percent identity with H. sapiens.
Full length sequences for the Chd1 protein for Homo sapiens (AAB87381.1), Mus
musculus (NP_031716.2), Xenopus laevis L (XP_018119985.1), Xenopus laevis S
(XP_018099827.1),

Danio

rerio

(NP_001121770.2),

Drosophila

melanogaster

(NP_477197.1), Caenorhabditis elegans (NP_491994.2), and Saccharomyces cerevisiae
(NP_011091.1) were retrieved from NCBI. The sequences were aligned with Clustal
Omega to determine the percent identity with H. sapiens.
The sequence corresponding to the chromodomains and helicase domain for H.
sapiens, M. musculus, D. rerio, D. melanogaster, C. elegans, and S. cerevisiae were
identified by accessing the Chd1 sequence on the NCBI protein database and choosing
the graphics format to determine the position of these domains within the sequence. The
helicase domain was represented by the span of sequence that included the SNF2 family
N-terminal domain and the helicase conserved C-terminal domain. The full length protein
sequences for Chd1 in all species mentioned above were aligned with the full length
protein sequence for Chd1 in X. laevis by utilizing Clustal Omega. The overlapping region
corresponding to the chromodomains and helicase domains from the analyzed species
was used to determine the position of the chromodomains and helicase domain in X.
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laevis. The percent identity with H. sapiens for the chromodomains and helicase domain
for each species was determined with the multiple alignment in Clustal Omega.
The DNA binding domain was identified in M. musculus (Delmas et al., 1993). The
sequence corresponding to the DNA binding domain in the other species was identified
by performing a multiple alignment with Clustal Omega between the full length Chd1
protein for M. musculus and the full length Chd1 protein sequence for the other analyzed
species. The percent identity was determined with the multiple alignment in Clustal
Omega.

6. RT-PCR to detect chd1 expression levels and splicing defects in morphants

a. Isolating tissues
To determine if chd1 was expressed at various stages of development, RNA was
isolated from 10 whole embryos that were at the unfertilized, 1-cell, blastocyst, and
gastrulation stages. To investigate chd1 expression at stages 24 (26-27.5 hpf), 30 (3537.5 hpf), 35 (50-53.5 hpf), and 40 (66-76 hpf), RNA was isolated from 15 embryo heads
at each stage. The heads were removed from the body of fixed embryos with a scalpel.
This was done by first making a cut through the body at the posterior end of the gut. Then
the head was removed with a second cut at the anterior end of the gut.
To determine the efficiency of Chd1-MO1, RNA was isolated from 10 whole
embryos at stage 26 (29.5-31 hpf).
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b. RNA extraction and cDNA synthesis
Isolated tissues were collected in 1ml of Trizol (Ambion 15596026). The tissues
were mechanically homogenized with a sterile, disposable pestle. The solution was
centrifuged at 14,800g for 10 minutes at 4°C to separate the soluble and insoluble
portions. The soluble portion was moved to a clean tube and the insoluble portion was
discarded. 200µl of chloroform was mixed with the soluble portion. The mixture was
centrifuged at 12,000g for 30 minutes at 4°C to separate the phases. The aqueous phase
was moved to a clean tube, while the remaining phase was discarded. 500µl of isopropyl
alcohol was added to the aqueous phase to precipitate the RNA. This mixture was
centrifuged at 12,000g for 20 minutes at 4°C to collect the precipitated RNA at the bottom
of the tube. The isopropyl alcohol was removed and the precipitated RNA was washed
with 1ml of 70% ethanol. This was centrifuged at 7500g for 10 minutes at 4°C to collect
the precipitated RNA at the bottom of the tube. The ethanol was removed and the RNA
was resuspended in 50µl of nuclease free water. The resuspended RNA was mixed with
25µl of a lithium chloride solution (Ambion AM9480) and incubated overnight at -20°C.
This mixture was centrifuged at 14,800g for 30 minutes at 4°C. The lithium chloride
solution was removed and discarded. The RNA was washed in 1ml of 70% ethanol. This
was centrifuged at 14,800g for 30 minutes at 4°C. The ethanol was removed and the RNA
was resuspended in 20μl of nuclease free water.
1μg of RNA was used to synthesize cDNA using the Qiagen quantitect reverse
transcription kit (Qiagen 205311) or the biosystems high capacity cDNA reverse
transcription kit (Thermofisher 4368814).
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c. RT-PCR
RT-PCR was performed with Apex 2x hotstart taq master mix (Cat. Number 42144) on a BioRad MJ Mini Personal Thermocycler. Primers were designed to target the
3’ end of chd1 to determine expression of chd1. These primer sequences were Chd1-F:
GGTCAGTTCCCATGAAGAAG and Chd1-R: ATGAGCAGCTTTGGTGTG.
Primers were designed to target exon 1 and exon 3 of chd1 to determine the
efficiency of Chd1-MO1 to block splicing. Chd1MO1-F: GCGATGAAGACAATGTAAGC
targeted exon 1 and Chd1MO1-R: CATCTGAGCCACTGTTTGAA targeted exon 3 of
chd1. Exon 2 was predicted to be absent in the product of this reaction. To translate the
predicted product, exon 2 of chd1 was identified on xenbase.com and the chd1 sequence
without exon 2 was translated using A Plasmid Editor software.
The PCR products were analyzed on a 2% agarose gel prepared with molecular
grade agarose (Bioline BIO-41025) in TAE buffer.

d. qRT-PCR of craniofacial genes
RNA was isolated from 30 embryo heads using the Trizol method followed by a
lithium chloride precipitation as described in section 6B. cDNA was prepared using the
applied biosystems high capacity cDNA reverse transcription kit (Thermofisher 4368814).
qRT-PCR was performed with SensiFAST SYBR No-Rox (Bioline BIO-98002) on a BioRad CFX96 Real Time PCR system. The relative amounts of amplification were
calculated using the delta-delta CT method and were normalized to expression levels of
GAPDH. Primer sequences are in table 1.2.
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e. qRT-PCR for Chd1 expression after exposure to RAR agonist
qRT-PCR was performed as described in section 6d. The relative amounts of
amplification were calculated using the delta-delta CT method and were normalized to
expression levels of actin. Primer sequences are in table 1.2.

7. In situ hybridization

a. Probe preparation
DIG labeled RNA probes for Chd1 were prepared using a plasmid template
containing a partial sequence for Xenopus Chd1 from Dharmacon (Catalog #: MXL1736202727035, Clone ID: 6643113, Genbank #: BC094094). This sequence targeted the 3’
end of chd1 including a portion of the 3’ UTR generating a probe that was 2894 base
pairs in length. BLAST (NCBI) analysis suggested this sequence was specific to Chd1
and not well conserved with other CHD proteins.
The plasmid was linearized with SacI (NEB R0156S) for synthesis of the antisense
probe. While the plasmid was linearized with Mlul (NEB R0198S) for synthesis of the
sense probe. The restriction digest reactions were purified by gel extraction (Qiagen
Qiaquick gel extraction kit, Qiagen 28706). 2μg of template DNA was used in a 20μl
reaction containing 1X transcription buffer (NEB B9012S), 1X DIG RNA labeling mix
(Roche 11277073910), 40 units RNAsin (Bioline BIO-65027), and 1X T7 RNA polymerase
(NEB M0251S) for the antisense probe, or 1X SP6 RNA polymerase (NEB M0207S) for
the sense probe. The reactions were incubated in a 37°C water bath for 5 hours. After
incubation, 30µl of nuclease free water and 25µl of a lithium chloride solution (Ambion
AM9480) were added to the reaction tube and incubated overnight at -20°C. This mixture
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was centrifuged at 14,800g for 30 minutes at 4°C. The lithium chloride solution was
removed and discarded. The RNA was washed in 1ml of 70% ethanol. This was
centrifuged at 14,800g for 30 minutes at 4°C. The ethanol was removed and the RNA
was resuspended in 20μl of nuclease free water. Since the probe was large (3894 base
pairs) and did not work well in preliminary experiments, hydrolyzation was utilized to
create shorter fragments of the probe (expected to be about 300 base pairs) (Sive et al.,
2000). To do this, 1μg of probe was hydrolyzed in 40mM sodium bicarbonate and 60mM
sodium carbonate for 60 minutes at 60°C. The hydrolyzed probe was precipitated in a
solution containing 200µl water, 25μl 3M sodium acetate, and 600μl ethanol. The solution
was centrifuged at 14,800g for 10 minutes. After centrifugation, the supernatant was
removed and the probe was resuspended in 20µl of nuclease free water.

b. Hybridization and visualization
In situ hybridization was performed as described in (Sive et al., 2000), omitting the
proteinase K treatment. Embryos were fixed in 4% PFA overnight at 4°C. After three
washes in PBT, embryos were dehydrated in a methanol series in PBT: 25% to 50% to
70% to 80% to 90% to 100%. Once in 100% methanol, embryos were incubated overnight
at -20°C. The embryos were rehydrated by reversing the methanol series and ending in
PBT. After three washes in PBT, embryos were rinsed twice in 0.1M triethanolamine. The
embryos were then incubated in a mixture of 12.5μl acetic anhydride and 4ml of 0.1M
triethanolamine and this was repeated twice. Next, the embryos were washed three times
in PBT and bleached (1.5% hydrogen peroxide and 5% formamide in 2X SSC) on a light
box. Embryos were washed in 2X SSC followed by two washes in PBT. Next, embryos
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were incubated in hybridization buffer (50% formamide, 5X SSC, 5mg/ml torula RNA,
0.1% tween-20, and 50μg/ml heparin) at 60°C overnight. The embryos were incubated
with the hydrolyzed probe in hybridization buffer overnight at 60°C. Unbound probe was
washed out by first incubating in warm hybridization buffer at 60°C, then four washes in
2X SSC at 60°C, followed by four washes in 0.2X SSC at 60°C for 45 minutes each. There
was an additional wash in 0.2X SSC at room temperature and then three washes in maleic
acid buffer (MAB) (150mM maleic acid, 100mM NaCl, 0.1% tween-20, 7.9g/L NaOH, pH
7.5) for 30 minutes each. This was followed by an incubation in block solution (10%
Blocking reagent (Roche 11096176001), 10% lamb serum, 80% MAB) for 3 hours at room
temperature. Embryos were incubated overnight at 4°C in 0.63μl of anti-Digoxigenin-AP
(Roche 11093274910) diluted in 1ml of block solution. The embryos were washed six
times in MAB and two times in alkaline phosphatase (AP) buffer (50mM Tris pH 9.5,
50mM NaCl, 25mM MgCl2, 0.05% tween-20, 20g/L PVA) for 30 minutes each. Finally,
bound probe was detected with NBT/BCIP (36μl 50mg/ml NBT (Promega S380C) and
28μl 50mg/ml BCIP (Promega S381C)) in 10ml of AP buffer with 1mM levamisole (Acros
Organics 187870100). The staining reaction was stopped with two washes in AP buffer
followed by two washes in PBT. Embryos were fixed in 4% PFA overnight at 4°C and then
washed three times in PBT. Embryos were imaged as described in section 4C.

8. Morpholino knockdown

Antisense

morpholinos

were

purchased

CTAGTCACTTTACCTCTTGCTCCATC

from

GeneTools;

Chd1MO1:
Chd1MO2:

CTTCATCGCTATGTCCATTCATTGT. A standard control morpholino was obtained from
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GeneTools. Microinjections were performed using an Eppendorf femtojet microinjector
and a Zeiss Discovery V8 stereoscope. Embryos were placed in a dish lined with nylon
Spectra mesh (1000 μm opening and 1350 µm thickness) at the bottom to hold embryos
in place and filled with 3% Ficoll 400 (Fisher Bioreagents BP525) dissolved in 0.1X MBS.
The injections were performed at the 1-cell stage. After injection, embryos were moved
to a dish containing 0.1X MBS and raised to stage 43 (87-92 hpf) at 15°C. Embryos were
fixed in 4% PFA overnight at 4°C and were then washed three times in PBT. Images were
taken as described in section 4 A-B.

9. Measurements and morphometrics

Measurements were performed with Axiovision40 software (Zeiss) based on the
method described in (Kennedy and Dickinson, 2014a, b). Face height was determined on
frontal views of embryo faces by measuring the distance from the top of the eyes to the
top of cement gland along the midline. The intercanthal distance was determined by
measuring the distance between the eyes. Measurements are expressed in µm.
Twenty-seven landmarks were chosen to represent the shape of the face for
geometric morphometric analysis. These landmarks were placed on images of the
embryo faces by utilizing the pointpicker plugin of ImageJ software (NIH). The coordinates
of these landmarks were entered into MorphoJ software (Klingenberg et al., 2010) to align
the data by procrustes fit and eliminate information about scale, size, position, and
orientation. A canonical variate analysis (CVA) was used to determine the variance
between groups relative to the variance within each group. This analysis converted
variance into components. These components, also known as canonical variates, were
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displayed in a scatter plot to illustrate the relationship between the analyzed groups. The
further the distance between canonical variates, the more different those groups were.
This data was also displayed as a three dimensional transformation grid for Chd1-MO1
morphants to show the relative changes of the landmark positions of the morphants
compared to control embryos. A discriminate function analysis (DFA) was utilized to
examine the relationship between embryos treated with the RAR inhibitor (BMS-453),
Chd1-MO1 morphants, and their respective controls. The output of the DFA was
displayed on a three dimensional transformation grid.

10. Alcian blue staining

Cartilages were stained using standard protocols (Taylor and Van Dyke, 1985)
with some modifications. Embryos were fixed in Bouins fixative overnight at 4°C. The
fixative was washed out in 70% ethanol. Next, embryos were immersed in alcian blue
stain (0.1mg/ml alcian blue (Sigma A-5268) in 1 part acetic acid and 4 parts ethanol) for
4 days at room temperature. Embryos were washed in 1% HCl in 70% ethanol four times.
Next, the embryos were rehydrated through an ethanol series in PBT: 70% ethanol to
50% ethanol to 25% ethanol to 100% PBT. Embryos were fixed in 4% PFA for two hours
followed by three washes in PBT. Next, the embryos were bleached (1.5% hydrogen
peroxide and 5% formamide in 2X SSC) on a light box. After three washes in PBT, the
embryos were incubated in 2% KOH three times. Finally, the embryos were cleared in a
series of 2% KOH and glycerol: 50% KOH and 50% glycerol to 40% KOH and 60%
glycerol to 20% KOH and 80% glycerol to 100% glycerol. Facial cartilages were imaged
in 100% glycerol.
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11. Flow Cytometry

50 embryo heads were dissected as described in section 6A and collected in 1X
MBS on ice. Single cells were obtained using a protocol adapted from (Lee et al., 2012).
The tissues were mechanically digested in 0.5X calcium free Ringer’s solution (58 mM
NaCl, 1.45 mM KCl, 2.5 mM HEPES, pH 7.2). The cells were washed three times in 0.5X
calcium free Ringer’s solution and two times in 1X PBS. Cells were dissociated by
incubating them in 0.25% Trypsin/EDTA (Sigma T4049) and 5 mg/mL collagenase type
2 (Worthington LS004174) for 20 minutes at 37°C. The suspension was passed through
a 40µm cell strainer (Greiner Bio-One 542040) and centrifuge at 3000 rpm for 2 minutes
at 4°C. Cells were resuspended in 5% goat serum in 1X PBS and centrifuged at 3000
rpm for 2 minutes at 4°C. Finally, cells were labeled with propidium iodide staining solution
(100 mM Tris pH 7.5, 154 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.2% Bovine Serum
Albumin (BSA), 0.1% Nonidet P-40, 86 µg/mL RNAse A (Thermoscientific EN0531), and
20 µg/mL propidium iodide) for 1 hour. Cells were passed through a cell strainer prior to
analysis on the flow cytometer. Cells were analyzed with a Canto - BD FACSCanto II
Analyzer.

12. Immunohistochemistry

Embryos were fixed in 4% PFA for two hours at room temperature. After three
washes in PBT, embryos were dehydrated in a methanol series: 25% to 50% to 70% to
80% to 90% to 95% to 100%. Next, embryos were bleached (1% hydrogen peroxide in
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methanol) for several days until bleached. After rehydrating the embryos through the
reverse of the methanol series, the embryos were washed three times in PBT.
Endogenous alkaline phosphatases were inactivated by incubating embryos in
hybridization buffer (50% formamide, 5X SSC, 5mg/ml torula RNA, 0.1% tween-20, and
50µg/ml heparin) for three hours at 65°C. After five washes in PBT, embryos were
incubated in block solution (1% goat serum, 5% BSA, 0.1% triton) overnight at 4°C. Next,
the embryos were incubated with anti-rabbit cleaved caspase 3 antibody (Cell Signaling
9661S) diluted 1:1000 in PBT overnight at 4°C. After three washes in PBT, embryos were
incubated in goat anti-rabbit AP secondary (Cat. # 0751-1506) diluted 1:500 in PBT
overnight at 4°C. The embryos were washed three times in PBT and then three times in
AP buffer (50mM Tris pH 9.5, 50mM NaCl, 25mM MgCl2, 0.05% tween-20, 20g/L PVA)
with 2mM levamisole. The color was developed by incubating embryos with NBT/BCIP
(Roche 11697471001) in AP buffer. The coloration reaction was stopped by washing the
embryos two times in AP buffer then two times in PBT with 5mM EDTA. Embryos were
fixed in 4% PFA and then imaged after three washes in PBT.

13. RARE analysis

The 10kb sequence upstream of the transcription start site for each gene was
retrieved from xenbase.org. These sequences were examined for transcription factor
binding sites using PATCH public 1.0 software. The parameters were set to scan
vertebrate sites with a minimum site length of 6 and 0 mismatches. The mismatch penalty
was set at 100 with a lower score boundary of 87.5. The output was examined for the
frequency of RAR binding sites.
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14. Statistical analysis

Chi-square test was utilized to determine if differences in phenotype prevalence
were statistically significant. Kruskal-Wallis test by ranks was utilized to determine if
differences in facial size measurements were statistically significant. Student’s t-test
was utilized to determine if differences in expression based on qRT-PCR analysis were
statistically significant.
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RESULTS

1. Transcriptional regulators are required for orofacial development

Orofacial development is a complex process involving multiple signals to shape
this region. With the multifaceted nature of this signaling network, it takes an intricate
system of transcription and epigenetic factors to regulate a cell’s response (Chai and
Maxson, 2006; Jiang et al., 2006; Szabo-Rogers et al., 2010). Retinoic acid is one signal
involved and was used here to investigate changes to transcriptional regulators during a
specific time window of orofacial development (Kennedy and Dickinson, 2012).

a. Inhibition of retinoic acid receptor function results in decreased expression of
transcriptional regulators

Inhibition of retinoic acid receptors during early orofacial development results in
embryos with a median cleft (Kennedy and Dickinson, 2012). Expression analysis of the
orofacial tissues of these embryos revealed that transcriptional regulators represented
the group that was most altered in response to decreased RAR function (Wahl in prep).
This data was analyzed to identify genes that were decreased by at least 1.5 fold and
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were also involved in 1) chromatin regulation, 2) histone modification, 3) transcriptional
elongation, or 4) transcriptional initiation (summarized in table 1.3). This analysis revealed
twelve chromatin regulators which included seven ATP-dependent chromatin remodelers,
four histone chaperones, and one chromatin organizer. In addition, nine histone modifiers
which included two histone acetyltransferases, one histone deacetyltransferase, five
histone methylases, and one histone demethylase were identified. Finally, three
transcriptional elongation factors and one transcriptional initiation factor were identified.
Further scrutiny of these proteins revealed that a subset are involved in regulation
of retinoic acid receptor function. Histone deacetylases and SWI/SNF chromatin
remodeling complexes are known to be recruited by corepressors and coactivators bound
to retinoic acid receptors to regulate retinoic acid signaling (Niederreither and Dolle,
2008). The identification of a histone deacetylase and members of the SWI/SNF family in
the expression analysis suggest that retinoic acid receptor function may be necessary to
maintain expression of genes encoding proteins essential for its own regulation. Further,
this analysis may also indicate novel players such as CHD proteins in the regulation of
retinoic acid receptor function.

b. Inhibition of transcriptional regulators during early orofacial development can cause
midface defects

Next, two of the identified transcriptional processes were perturbed to determine if
they are generally required during early orofacial development. To test this, embryos were
exposed to pharmacological inhibitors that target transcriptional elongation and histone
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deacetylation. These embryos were treated using the same experimental procedure as
those embryos treated with the retinoic acid receptor inhibitor (Kennedy and Dickinson,
2012). In brief, embryos were treated with a pharmacological inhibitor from stage 24 (2627.5 hpf) to 30 (35-37.5 hpf). After the treatment, the embryos were removed from the
antagonist and were then raised to stage 42-43 (80-92 hpf) for analysis (Fig. 1.2A).
One prominent category identified in the expression analysis was transcriptional
elongation. This included the genes tceb3, rtf1, and isw1, and additionally, the chromatin
regulators chd1 and spt16 that also function to facilitate this process were identified as
well. To inhibit transcriptional elongation, leflunomide, which has been shown to
effectively inhibit transcriptional elongation and cause craniofacial defects in zebrafish
(White et al., 2011) was utilized. Leflunomide works by inhibiting dihydroorotate, an
enzyme involved in the biosynthesis of pyrimidine, thus, reducing the nucleotide pool
(McLean et al., 2001). Results revealed that 100% of embryos exposed to leflunomide
had smaller faces indicated by a reduced intercanthal distance of at least 25% (n=20, 2
biological replicates, p-value = 2.5E-10; Fig. 1.2B, D, F, H). This result suggests that
transcriptional elongation is an important process during this early stage of facial
development. Since transcriptional elongation occurs in a chromatin environment in a cell,
this raised the question of the importance of chromatin regulation during this process.
Another prominent category identified was histone modification, therefore the
effect of repressive histone modifications, namely histone deacetylation, on early facial
development was investigated. Histone deacetylation by HDACs causes a tighter
association between histones and DNA, thereby inhibiting transcription (de Ruijter et al.,
2003). These proteins play a role in transcriptional repression of genes targeted by
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retinoic acid in the absence of retinoic acid binding to receptors (Urvalek and Gudas,
2014). Inhibition of histone deacetylation with the HDAC inhibitor, Trichostatin A, has
been shown to result in histone hyperacetylation and inhibition of the cell cycle in
zebrafish (Ignatius et al., 2013). Trichostatin A inhibits class I, II, and IV HDACs (Yoshida
et al., 1995) and works through an interaction with zinc ion at the catalytic active site,
thereby chelating this metal ion that is necessary for nucleophilic attack on the substrate
employed by HDACs to hydrolyze acetyl-L-lysine side chains in histone proteins (Finnin
et al., 1999; Lombardi et al., 2011). Results revealed that 100% of embryos exposed to
Trichostatin A had a smaller face, mouth, and eyes (n=20, 2 biological replicates, p-value
= 2.5E-10; Fig. 1.2C, E, G, I). Furthermore, these embryos had abnormally shaped
mouths that were more round in shape compared to controls suggesting that proper
regulation of histone acetylation and deacetylation is necessary for early orofacial
development. Together, these results highlight that the transcriptional processes of
elongation and histone deacetylation are generally required during early orofacial
development.

2. Chd1 is important for facial development in Xenopus laevis

The results in the previous section suggested that not surprisingly, transcriptional
regulation is indeed critical for orofacial development. Next, the focus was turned to one
particular regulator, Chd1, which was identified in a microarray expression analysis of
face tissues that were deficient in retinoic acid signaling and was among the most highly
altered genes in this analysis. This gene represented a novel regulator that has not been
previously examined in orofacial development. Previous work in the lab has also validated
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this microarray expression analysis using RT-PCR with two different primer sets
(unpublished and Wahl et al in prep). To determine whether Chd1 is required for orofacial
development, a series of classic developmental experiments was performed. First, a
multiple alignment was utilized to establish whether Chd1 was conserved between frogs
and other species. Next, the localization of chd1 expression was investigated with in situ
hybridization. Finally, Chd1 expression levels were reduced to gain insight into the role of
this chromatin remodeler. Further, the changes in the face of embryos with reduced Chd1
expression

were

quantified

through

traditional

measurements

and

geometric

morphometric analysis.

a. The Chd1 gene and protein is well conserved across vertebrates

Evidence from yeast, flies, mice, and humans suggest Chd1 functions as a
chromatin remodeler across metazoans (Hall and Georgel, 2007). If this protein has
similar functions across such phyla, then it would be expected that the gene, protein, and
domain structure would be well conserved. To test this hypothesis, gene, protein and
domain sequence alignments were performed. The open reading frame of the chd1 gene
from Mus musculus, Xenopus laevis, Danio rerio, Caenorhabditis elegans, Drosophila
melanogaster, and Saccharomyces cerevisiae was aligned with Homo sapiens.
First, the L and S forms of chd1 in X. laevis were aligned. These two forms are the
result of a genome duplication that resulted in allotetraploidy in X. laevis. This alignment
revealed that the L and S forms are 95% identical. Next, both the L and S forms were
compared with the other species and this alignment revealed that the chd1 gene is well
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conserved. The L and S forms of X. laevis chd1 were 77.63% and 78.12% identical to
human CHD1 respectively. This was 10% less than mice and 7% more than zebrafish.
Overall, this represents conservation among vertebrates. There was, as expected, less
similarity with the invertebrate species. D. melanogaster was 53.20% identical, C. elegans
was 54.86% identical, and S. cerevisiae was 50.37% identical to human chd1 (Table 1.4).
Next, the Chd1 protein was compared between these species. First, the L and S
forms of X. laevis Chd1 were aligned and this analysis revealed that they were 96%
identical. Next, these sequences were aligned with the other species. The L and S forms
of X. laevis Chd1 were 84.93% and 85.46% identical to human Chd1. This was 11% less
identical than mouse Chd1 and 5% more identical than zebrafish Chd1. There was less
conservation with the invertebrate species. D. melanogaster was 49.48% identical, C.
elegans was 47.11% identical, and S. cerevisiae was 38.43% identical to human Chd1
(Table 1.4). This result prompted a closer examination of the functional domains of Chd1.
The chromodomains, helicase domain, and DNA binding domains are presumably
critical for the function of Chd1 and conservation of these would be further evidence of
conserved function. The organization of the protein domains were analyzed and this
revealed that the organization was similar between these species (Fig. 1.3). Next, a
multiple alignment of these domains was performed to determine the identity between the
species. The L and S forms of X. laevis chromodomain 1 was 78% and 80% identical to
human chromodomain 1. This was 17% less than mouse and 7% less than zebrafish. D.
melanogaster was 57.14% identical, C. elegans was 51.11% identical, and S. cerevisiae
was 56.10% identical to human chromodomain 1. The L and S forms of chromodomain 2
were both 90.74% identical to human chromodomain 2. This was 4% less than mouse
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and only 0.17% more than zebrafish. D. melanogaster was 48.08% identical, C. elegans
was 34.04% identical, and S. cerevisiae was 28.85% identical to human chromodomain
2 (Table 1.4).
Next, the helicase domain was aligned and this revealed that this domain was the
most conserved between these species. The L and S forms of X. laevis were 94.51% and
93.56% identical with the human helicase domain. This was 5% less than human and 1%
more than zebrafish. D. melanogaster was 74.22% identical, C. elegans was 69.78%
identical, and S. cerevisiae was 54.89% identical with the human helicase domain (Table
1.4).
Finally, the DNA-binding domain was aligned and this revealed that there was
strong conservation among vertebrates. The L and S forms of the X. laevis DNA binding
domain were 90.75% and 91.67% identical to human DNA binding domain. This was 7%
less than mouse and 3% more than zebrafish. D. melanogaster was 48.66% identical, C.
elegans was 38.35% identical, and S. cerevisiae was 30.35% identical to the human DNA
binding domain sequence (Table 1.4). Together, these results suggest that Chd1 is
conserved across phyla and likely has a similar function in these species.

b. Chd1 is expressed during early development in the head and presumptive heart of X.
laevis embryos

Next, the spatiotemporal expression of Chd1 during X. laevis development was
investigated. The temporal expression of chd1 was examined by utilizing reverse
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transcription polymerase chain reaction (RT-PCR) at various stages of development.
Next, the spatial expression of chd1 was examined by utilizing RNA in situ hybridization.
The expression of chd1 was examined with RT-PCR at eight different stages to
determine when chd1 is expressed during early development in X. laevis. Expression was
examined in whole embryos at the unfertilized, 1-cell, blastula, and gastrulation stages.
Further, expression was also examined in embryonic heads at stages 24 (26-27.5 hpf),
30 (35-37.5 hpf), 35 (50-53.5 hpf), and 40 (66-76 hpf). This analysis revealed that chd1
was expressed at all eight of these stages of development (Fig. 1.4A). In agreement with
these results, mouse chd1 is expressed maternally and through pre-implantation
development (Guzman-Ayala et al., 2015). Together, these results suggest that Chd1 has
an important role during early embryonic development in X. laevis.
Next, the spatial localization of chd1 at various stages was examined by utilizing
RNA in situ hybridization to gain more insight into the role of Chd1 during early embryonic
development. At stage 24-25 (26-29.5 hpf), chd1 was expressed throughout the head
with enriched expression in the eye and a stripe under the eye. Expression was absent
in other areas of the embryo at this stage (Fig. 1.4Bi, i’, ii). At stage 29-30 (35-37.5 hpf),
chd1 was expressed in the face with an enrichment in the developing eye, otic vesicle,
and in the branchial arches. During early tadpole stages (stage 34-35, 44.5-53.5 hpf) chd1
expression was localized in regions around the eye, the brain, the anterior face, and the
presumptive heart (Fig. 1.4Bv, v’, vi). Finally, at stage 40 (66-76 hpf), chd1 was localized
to the head and face, with enriched expression around the eye and in the brain ventricles
(Fig. 1.4Bvii, vii’, viii). The expression on the dorsal side of the tail observed at stages 3435 (44.5-53.5 hpf) and 40 (66-76 hpf) was also observed faintly in the respective sense
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controls. Therefore, the expression observed in the tail may not be specific to chd1
expression. Together, these results suggest Chd1 could have a role in craniofacial
development and prompted further investigation into this possibility.

c. Decreased Chd1 results in developmental defects including abnormal orofacial
development

To investigate the role of Chd1 in the development of the face, an antisense oligo
(Morpholino (MO), Gene Tools) was utilized to reduce Chd1 levels and evaluate the
effect. Chd1-MO1 was designed to bind to the splice donor site at the exon 2 - intron 2
boundary and inhibit access of the splicing machinery to this region of the pre-mRNA. It
was predicted that this would result in a splicing defect that would lead to the deletion of
exon 2. To test this, RT-PCR was utilized to determine whether this MO could in fact
cause a splicing defect. More specifically, this RT-PCR assay was designed to determine
whether binding of this MO would result in the deletion of exon 2. RNA was extracted
from embryos injected with 65-75ng of Chd1-MO1 or an equal amount of a standard
control morpholino (Fig. 1.5A). The RNA was isolated from the embryo heads at stage
29-30 (35-37.5 hpf). Primers specific to exon 1 and exon 3 of chd1 were used to determine
whether exon 2 was present based on the size of the amplified PCR product. A PCR
product of 339 base pairs would indicate that exon 2 was still present and Chd1-MO1 did
not block splicing as expected. However, a PCR product of 152 base pairs would indicate
exon 2 was deleted and Chd1-MO1 effectively blocked splicing. The result of this PCR
assay revealed that the smaller 152 base pair product was present in RNA from Chd1-
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MO1 morphants, therefore suggesting that exon 2 was deleted in these morphant
embryos (Fig. 1.5A-B). Translation of the chd1 sequence without exon 2 revealed
numerous stop codons beginning with one in exon 3. This suggests that the altered chd1
sequence would not likely produce a functional Chd1 protein.
Next, the effect of reduced Chd1 levels was examined by injecting embryos with
Chd1-MO1 at the 1-cell stage. Embryos injected with 15-25ng of Chd1-MO1 developed
normally and embryos injected with 35-45ng of Chd1-MO1 had a mild reduction in the
size of the embryo head. Embryos injected with 65-75ng of Chd1-MO1 displayed several
developmental defects and this amount was chosen for use in further investigations. Chd1
expression was reduced by injecting 65-75ng of Chd1-MO1 at the 1-cell stage and
examining embryos at stage 43 (87-92 hpf). This morpholino was fluorescently tagged so
that the embryo could be visually assessed after injection. The injected embryos were
manually sorted based on similar fluorescence intensity and similar expression pattern of
the fluorescence through the embryo. Embryos with similar intensity and expression
pattern of fluorescence would indicate that these embryos received a similar amount of
Chd1-MO1, and thereby, reducing the amount of variability in the morphants. 100% of
Chd1-MO1 morphants were smaller than embryos injected with control morpholino.
Further, the tail curved ventrally in 55% of Chd1-MO1 morphants. There was also edema
observed in the anterior ventral region, near the developing heart and gut, in 85% of
Chd1-MO1 morphants. In 55% of Chd1-MO1 morphants, there was blistering in the skin
along the edges of the tail (Fig. 1.5C-D).
Closer inspection of the face revealed that 100% of Chd1-MO1 morphants had
narrower faces. The mouth was smaller and more circular in shape in 88% of Chd1-MO1
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morphants compared to control embryos. Furthermore, in a subset of these morphant
embryos, the mouth was missing. Finally, there were eye defects in 36% of Chd1-MO1
morphants. These defects included smaller eyes, abnormally shaped eyes, and in some
cases, missing eyes (Fig. 1.5C-D). The variability may have been due to the difficulty of
injecting the exact same amount of morpholino into every embryo. While careful sorting
of the injected embryos based on fluorescence can reduce variability, it does not
completely eliminate the variability. Together, these results suggest Chd1 is important for
development of the face. Further, the narrowing of the face prompted me to quantify the
changes in the size and shape of the face in Chd1 morphants.
The narrowing of the face in Chd1-MO1 morphants may be the result of defects in
the development of the midface. Tissue deficiencies in midface development can lead to
median craniofacial hypoplasia. This may result in defects in the development of the
forebrain, the nasal structures, and the palate (Allam et al., 2011). The intercanthal
distance, or distance between the eyes, and the face height were measured to investigate
whether there were deficiencies in the development of the midface in Chd1-MO1
morphants.
The intercanthal distance was decreased by 52% in Chd1-MO1 morphants when
compared to controls (p-value < 0.001, n = 33, 3 biological replicates Fig 1.6A). While the
face height was increased by 21% in Chd1-MO1 morphants compared to controls (pvalue < 0.001, n = 33, 3 biological replicates Fig 1.6A). Further, the intercanthal to face
height ratio in control embryos was 2.10, while the ratio in Chd1-MO1 morphants was
0.80. Therefore, the intercanthal distance was twice the face height in control embryos,
while the intercanthal distance was less than the face height in Chd1-MO1 morphants.
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These results suggest that the faces of Chd1-MO1 morphants were quantitatively
narrower. The next question was whether the faces of Chd1-MO1 morphants were simply
smaller or if there was a change in the shape of the face in these embryos as well.
Therefore, geometric morphometric analysis was utilized to examine the shape the
face of Chd1-MO1 morphants. Twenty-seven landmarks were chosen to represent the
shape of the face (Fig. 1.6B). These landmarks were aligned using MorphoJ software to
eliminate differences in the size of the embryos. Canonical variant analysis was utilized
on the data generated from this alignment to determine how loss of Chd1 affected the
shape of the face. This analysis revealed variability in Chd1-MO1 morphants, while there
was less variability in control embryos. Additionally, there was a statistically significant
difference between control and Chd1-MO1 morphant embryos (p-value < 0.0001) (Fig.
1.6C). This difference was highlighted when vectors showing the changes in landmark
position were superimposed on a transformation grid (Fig. 1.6D). This revealed that
landmarks were shifted inward toward the midline and outward toward the dorsal and
ventral regions of the head in Chd1 morphants. Together, these results suggest a role for
Chd1 in the development of the face.

d. The defects in morphants are specific to loss of Chd1

A second morpholino, Chd1-MO2, was utilized to ensure the phenotypic changes
in Chd1-MO1 morphants were specifically the result of reduced expression of Chd1. If
two different morpholinos resulted in similar phenotypic changes in morphant embryos,
then this would suggest that the changes were due to reduced expression of the targeted
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gene and not due to off target effects. This is because it is unlikely that two different
morpholinos would have the same off target effects, assuming these off target effects
were the cause of the phenotype.
Chd1-MO2 was designed to block translation by overlapping the translation start
site. Embryos were injected with 30-40ng of Chd1-MO2 at the 1-cell stage and examined
at stage 43 (87-92 hpf) (Fig. 1.7A-B). 35% of Chd1-MO2 morphants were smaller than
embryos injected with an equal amount of control morpholino. Further, in 25% of Chd1MO2 morphants, there was curvature in the tail. In some cases, this was similar to the
ventral curvature observed in Chd1-MO1 morphants. In other cases, the tail curved
dorsally, or appeared crooked and curved dorsally and then back ventrally. There was
also edema observed in the anterior ventral region near the developing heart and gut
similar to Chd1-MO1 morphants in 20% of Chd1-MO2 morphants. Also like Chd1-MO1
morphants, there was blistering of the skin along the edges of the tail in 20% of Chd1MO2 morphants (Fig. 1.7C-D).
Examination of the face revealed that 35% of Chd1-MO2 morphants had narrower
faces. Further, 55% of Chd1-MO2 morphants had smaller and misshapen mouths. The
shape was more circular compared to controls. Finally, 40% of Chd1-MO2 morphants had
eye defects. These defects included smaller eyes and misshapen eyes (Fig. 1.7C-D).
Together, these phenotypes were similar to those observed in Chd1-MO1 morphants.
However, there were differences in the percentage of morphant embryos displaying these
phenotypes. This may have been due to (1) the different type of morpholino used and (2)
the different amount of morpholino that was injected into embryos. Chd1-MO2 was a
translation blocking morpholino and this type of morpholino can sometimes have a
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stronger effect on embryos. This is because translation blocking morpholinos can bind to
maternally expressed messenger RNAs (mRNAs) and thereby, prevent translation of
these maternal transcripts. However, splice blocking morpholinos, such as Chd1-MO1,
will only bind to unspliced RNA and therefore, not have the early effect on maternally
expressed transcripts. The initial injections of Chd1-MO2 at higher concentrations caused
high incidences of embryonic death in injected embryos. Therefore, the amount that was
injected was reduced. Taken together, these two conditions may have contributed to
observed differences in the percentages of affected morphant embryos. Overall, the
similarities between Chd1-MO1 and Chd1-MO2 morphants suggest that the phenotypes
are the result of loss of Chd1 and not off target effects.

3. Decreased Chd1 results in changes in orofacial genes and cartilage development

The data in the previous section strongly suggested that reduced expression of
Chd1 resulted in changes in the size and shape of the developing face. This prompted
me to investigate potential mechanisms that may contribute to these changes. Since
Chd1 is a transcriptional regulator, the changes in Chd1 morphants may be due to
changes in gene expression in these embryos. Furthermore, the craniofacial cartilage and
bone provides structure to the face and changes in the facial cartilages may result in
changes in the size and shape of the face.
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a. Decreased Chd1 results in changes in orofacial genes

Chd1-MO1 morphants and embryos injected with a standard control morpholino
were raised to stage 29-30 (35-37.5 hpf) and then the heads of these embryos were
dissected for RNA isolation. Quantitative reverse transcription polymerase chain reaction
(qRT-PCR) was utilized to investigate the relative transcript levels of a subset of genes
highly expressed in the face and that were also downregulated upon RAR inhibition (Fig.
1.8A). These genes were normalized to gapdh expression to determine relative changes
in their expression. This analysis revealed that lhx8 expression was unaffected by
reduced expression of Chd1, while the expression of alx4 and pdgfra was slighted
elevated. Expression of the homeobox transcription factor, msx2, was reduced. Further,
expression of the neural crest gene, ap2, and the cartilage genes, has2 and six2, were
also reduced (Fig. 1.8B). This was an interesting result, especially considering that the
neural crest is known to contribute to craniofacial cartilage and bone development (Mayor
and Theveneau, 2013). The reduced expression of ap2, together with the reduced
expression of has2 and six2, may indicate that there are changes in the facial cartilages
in Chd1-MO1 morphants. Therefore, the facial cartilages in Chd1-MO1 morphants were
examined next.

b. Decreased Chd1 results in reduced and missing cartilages

The craniofacial cartilage helps provide the underlying structure as the base of
the shape of the face. Therefore, any changes in the development of the facial cartilage
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could lead to changes in facial shape. To investigate cartilage, Alcian blue staining was
utilized to compare the cartilages in Chd1 morphants and control embryos. Embryos were
injected at the 1-cell stage with 65-75ng of Chd1-MO1 or an equal amount of control
morpholino. Embryos were allowed to develop until stage 45 (98-106 hpf) when the
cartilages in the face have formed (Fig. 1.8C). The cartilages were well formed in control
embryos. However, the cartilages were reduced or missing in Chd1 morphants. This was
apparent in the reduced size of the ceratohyal and Meckel’s cartilages. The ceratohyal
cartilage helps form the floor of the mouth (Rose, 2009) and the Meckel’s cartilage helps
form the lower jaw (Altig and McDiarmid, 1999). Additionally, the ethmoid cartilage that
forms the roof of the oral cavity (Altig and McDiarmid, 1999) was missing in many Chd1
morphants (Fig. 1.8D). The changes in the cartilages were consistent with the reduced
size and defects observed Chd1 morphants.

4. Decreased Chd1 results in increased cell death

Decreases in cell proliferation or increases in cell death could also be a
contributing factor to the decreased size observed in Chd1 morphants. In mice there are
defects in the cell cycle and increased apoptosis in Chd1-/- embryos (Guzman-Ayala et
al., 2015). To investigate if this is also true in frogs, flow cytometry was utilized to
characterize the cell cycle profile in Chd1 morphants. Immunohistochemistry was also
utilized to detect phospho-histone H3, a marker for chromatin condensation of cells
entering into the mitotic phase (Hendzel et al., 1997), and cleaved caspase 3, a marker
for apoptotic cells (Elmore, 2007), to examine whether there were changes in cell death
in Chd1 morphants.
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a. Decreased Chd1 results in an increased number of cells in the sub-G1 fraction

The initial analysis began with investigating the cell cycle in Chd1 morphants. To
do this embryos were injected with 65-75ng of Chd1-MO1 or an equal amount of control
morpholino at the 1-cell stage. The heads of injected embryos were dissected and
collected at stage 29-30 (35-37.5 hpf) for cell dissociation and isolation. The cells were
labeled with propidium iodide for flow cytometry (Fig. 1.9A). There were small decreases
in the G0/G1, S, and G2/M phases of the cell cycle in stage 29-30 (35-37.5) Chd1-MO1
morphants, suggesting little change in cell proliferation (Fig. 1.9B). Consistent with this,
there was no change in phospho-histone H3 labeling in Chd1 morphants (Fig. 1.9C).
Interestingly, there was a larger proportion of cells in the sub-G1 fraction in Chd1-MO1
morphants (Fig. 1.9B). This fraction contains cells that have lost some of their DNA, which
happens primarily when cells are undergoing apoptosis (Arends et al., 1990; Nagata,
2000; Nagata et al., 2003). These results suggested that there may be an increase in cell
death in Chd1-MO1 morphants, and perhaps, this may also be a contributing factor to the
reduction in the size of morphant embryos.

b. Decreased Chd1 results in an increase in cleave caspase 3 positive cells

To investigate cell death further, immunohistochemistry was utilized to detect
cleaved caspase 3. To do this, Chd1-MO1 morphants were raised to stage 29-30 (3537.5 hpf). Next, a colormetric assay was used to detect bound cleaved caspase 3
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antibody in Chd1-MO1 morphants (Fig. 1.10A). There was a dramatic increase in the
number of cleaved caspase 3 positive cells in Chd1 morphants compared to control
embryos. These cleaved caspase 3 positive cells were enriched in the face, eyes, brain
region, and along the back of the embryo near the neural tube (Fig. 1.10B). Furthermore,
the regions containing an enrichment of cleaved caspase 3 positive cells are similar to
the regions containing an enrichment of chd1 expression (Fig. 1.4B). Together, these
results suggest that reduced Chd1 expression leads to increased apoptosis.

5. Chd1 cooperates with retinoic acid during orofacial development

Retinoic acid signaling is necessary for the development of the orofacial region.
Since inhibition of retinoic acid receptor function resulted in decreased levels of chd1, this
prompted me to investigate a potential connection between retinoic acid and Chd1. The
aim of this analysis was to determine whether the changes in facial development in Chd1
morphants was similar to embryos treated with a retinoic acid receptor inhibitor. In
addition, a bioinformatic approach was utilized to search for the presence of retinoic acid
receptor binding sites upstream of the Chd1 transcription start site.

a. Some changes in the facial shape are similar between Chd1 morphants and embryos
exposed to the RAR inhibitor

The size and shape of the face in X. laevis are altered when either Chd1
expression is decreased or RAR function is inhibited. This prompted an investigation of
how similar the changes were between these two groups. To do this, embryos were
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injected with 65-75ng of Chd1-MO1 or a standard control morpholino at the 1-cell stage
and raised to stage 43 (87-92 hpf), or exposed to 1µM of the RAR inhibitor from the 2-cell
stage (1.5-2 hpf) to stage 43 (87-92 hpf) (Fig. 1.11A). The treatment strategy with the
RAR inhibitor was extended, compared to the treatment strategy used in previous
experiments, so that it was more closely comparable to injection of Chd1-MO1. Next, the
intercanthal distance and face height were measured for both of these treatment groups.
The intercanthal distance was reduced by 52% and the face height was increased by
26% in Chd1 morphants compared to controls. In embryos exposed to the RAR inhibitor,
the intercanthal distance was reduced by 45% and the face height was increased by 20%
compared to controls (Fig. 1.11B-C). These results indicate that the face is narrower in
embryos with decreased Chd1 expression or exposure to a RAR inhibitor. Next, these
embryos were examined with morphometric analysis to determine if the changes in the
shape of the face were also similar.
Chd1 morphants and embryos exposed to the RAR inhibitor were analyzed using
27 landmarks that represented the shape of the face (Fig. 1.12A-B). The landmarks were
aligned by Procrustes fit and then examined with canonical variant analysis to determine
the similarity between the treatment groups. Canonical variate 1 accounted for 63.962%
and illustrates that Chd1 morphants and embryos exposed to the RAR inhibitor are
different from controls, which is indicated by the greater distance between clusters on the
canonical variate 1 axis. The clusters for Chd1 morphants and embryos exposed to the
RAR inhibitor are separated by a shorter distance along the canonical variate 1 axis,
suggesting that the faces of these embryos are more similar to each other than they are
to controls. Canonical variate 2 accounted for 30.891% and suggests that there are some
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differences between the faces of Chd1 morphants and embryos exposed to the RAR
inhibitor, based on the greater distance between clusters on the canonical variate 2 axis.
Canonical variate 3 accounted for 5.146% and illustrates that the faces of Chd1
morphants and embryos exposed to the RAR inhibitor are very similar based on the short
distance between clusters on the canonical variate 3 axis. Next, a discriminate function
analysis was utilized to examine the differences between Chd1 morphants and embryos
exposed to the RAR inhibitor. The results were presented as vectors superimposed on a
transformation grid in order to visualize the changes in the landmarks between these two
groups. There was not much difference between many of the landmarks, indicated by
short vectors, especially in the superior region of the face and in the midface. There were
some longer vectors in the inferior region of the face, near where the lower jaw develops.
Together, these results suggest that there are some similarities in the changes that occur
in the size and shape of Chd1 morphants and embryos exposed to the RAR inhibitor.

b. Retinoic acid binding sites are enriched in the 10,000 base pairs upstream of the Chd1
TSS

Chd1 may be regulated by retinoic acid directly. Therefore, a bioinformatics
approach was utilized to identify possible binding sites for RARs. RARs bind to retinoic
acid response element (RARE) sites and the presence of these in the region upstream of
the Chd1 transcription start site would support the potential for direct regulation of Chd1
by retinoic acid. The RARE consensus sequence is 5’-(A/G)G(G/T)TCA-3’ and is the
binding site for retinoic acid receptors (Rhinn and Dolle, 2012). PATCH software was
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utilized to identify RARE sites in the 10,000 base pairs upstream of the Chd1 transcription
start site. 53 RARE sites were found in this region (Fig 1.13). It is possible that the core
hexameric sequence could occur by chance alone. However, it would only be expected
for the sequence to occur by chance alone about 10 times in 10,000 base pairs. This
suggests that RARE sites are present in the region upstream of the Chd1 transcription
start site about 5X more than by chance alone. Other genes that are known to be targets
of retinoic acid, such as Fgf8 and Rai1 (Abe et al., 2008; Imai et al., 1995), have 41 and
46 sites respectively in the 10,000 base pairs upstream of their transcription start sites
(Fig. 1.13A-D). Therefore, the frequency of RARE sites upstream of Chd1 is similar to
known targets of retinoic acid.
RARE sites usually occur as a direct repeat spaced 1, 2, or 5 base pairs apart.
Therefore, a more stringent analysis was utilized to determine if any of the RARE
upstream of Chd1 occurred as a direct repeat. This analysis revealed that the RARE sites
upstream of Chd1 did not occur as direct repeats. Next, an alternative consensus
sequence, 5’-(A/G)G(G/T)T(G/C), was considered. This consensus motif was identified
from the alignment of known RARE motifs found in retinoic acid target genes that are
spaced five base pairs apart. This alignment included RARE motifs found in the promoters
of human and mouse genes involved in retinoic acid metabolism, retinoic acid signaling,
and in development (Lalevee et al., 2011). Analysis with this sequence revealed the
presence of one site that occurred as a repeat spaced 5 base pairs apart that was located
6212 base pairs upstream of the Chd1 transcription start site (5’-AGTTGAtttatAGGTGA3’), and may represent a site that is bound directly by retinoic acid receptors.
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c. Exposure to a RAR agonist increases Chd1 expression

The presence of a potential RARE site upstream of the Chd1 transcription start
site suggested the possibility that retinoic acid may directly regulate Chd1. To
investigate this further, stage 23 (25-26.5 hpf) embryos were exposed to 2.5µM an RAR
agonist (TTNPB) for four hours. At the end of treatment, RNA was isolated from these
embryos and analyzed with qRT-PCR. The results of this analysis revealed that the
expression of Chd1 doubled in response to exposure to the RAR agonist (Fig. 1-14A).
This result suggests that retinoic acid is upstream of Chd1, and together with a potential
RARE site upstream of the Chd1 transcription start site, supports the possibility that
retinoic acid directly regulates Chd1.

d. Comparison of expression of Chd1 and RARγ

The similarities in the face shape changes in Chd1 morphants and embryos with
reduced RAR function prompted further comparisons between these two groups. First,
comparison of Chd1 and RARγ expression revealed that there was enriched expression
of Chd1 in a region under the eye that was similar to the expression of RARγ at stage 2931 (35-40 hpf). Further, this expression is in a region that surrounds the developing future
mouth. At stage 40 (66-76 hpf), there was similar expression both under the eye and in a
region in the midface between the eye and the developing brain (Fig. 1-14B). Together,
the similarities in spatial localizations supports that Chd1 and retinoic acid may cooperate
to regulate gene expression.
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e. Comparison of cartilage defects between Chd1 morphants and embryos deficient in
RARγ function

The changes in the shape of the face between these two treatments may be
explained by similar changes in the craniofacial cartilages. To gain insight into whether
the changes in the cartilages were similar, embryos were exposed to 1µM of the RAR
inhibitor, BMS453, from the 2-cell stage (1.5-2 hpf) to stage 45 (98-106 hpf) or injected
with 65-75ng of Chd1-MO1 at the 1-cell stage and raised to stage 45 (98-106 hpf).
Overall, the cartilage defects were more severe in embryos exposed to the RAR inhibitor.
However, there were some similarities, particularly, in the more severe Chd1 morphants.
In embryos exposed to the RAR inhibitor, the ceratohyal and Meckel’s cartilages were
severely reduced and many of the other facial cartilages were missing and indiscernible.
This was similar to Chd1 morphants in which the ceratohyal and Meckel’s cartilages were
reduced and many of the other facial cartilages were missing and indiscernible (Fig.
1.14C). In the less severe Chd1 morphants, the ceratohyal and Meckel’s cartilages were
also reduced, but not as severely as these cartilages were in embryos exposed to the
RAR inhibitor. Together, the abnormalities in development of the craniofacial cartilages
between Chd1 morphants and embryos deficient in RARγ function further support the
possibility that Chd1 and retinoic acid cooperate to regulate gene expression.
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DISCUSSION

This study is the first to examine the role of Chd1 specifically in orofacial
development. Reduced Chd1 expression results in a narrower face, which correlates
with missing or smaller facial cartilages. Such defects could be caused by an increase
in cell death and defects in expression of genes required for neural crest development
and cartilage differentiation. Further, Chd1 may cooperate with retinoic acid to regulate
orofacial development.

Chd1 is required for craniofacial development in X. laevis

In mice, knockout of Chd1 results in embryonic arrest following implantation,
ultimately leading to the death and resorption of the embryo (Guzman-Ayala et al.,
2015). Therefore, the role of Chd1 in later developmental events, such as facial
development, could not be assessed in these studies. Here, titratable morpholinos were
utilized to reduce the levels of Chd1 and allow the embryo to proceed through early
development. By doing so, embryos did indeed have many defects beyond early
development such as defects in gut coiling, edema around the heart, skin blisters,
general overall smaller size, and craniofacial defects. Specifically, decreasing Chd1
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expression resulted in embryos with smaller mouths that were more circular in shape
compared to control embryos. The faces of Chd1 morphants were consistently narrower
with a reduced intercanthal distance. Further analysis utilizing geometric morphometrics
revealed significant changes in the shape of morphant embryo faces. Together, these
changes in the size and shape suggest defects in the development of the midface in
Chd1 morphants. These midface defects may represent changes in the growth and
merging of the facial prominences that form the orofacial region, resulting in the defects
observed in Chd1 morphants. Further, these defects may arise from changes in
important factors necessary for facial development.
Complete loss of Chd1 in mice leads to embryonic death before craniofacial
development can occur (Guzman-Ayala et al., 2015). However, other CHD family
members, specifically Chd7 and Chd8 are necessary for craniofacial development in
mice and humans (Basson and van Ravenswaaij-Arts, 2015; Platt et al., 2017; Sperry et
al., 2014). Chd7 is associated with CHARGE syndrome, which has features that are
similar to known neurocristopathies and can include defects such as orofacial clefts
(Pauli et al., 2017). Chd7 is expressed in premigratory and migratory neural crest cells
in Xenopus and in mice (Bajpai et al., 2010; Fujita et al., 2014). In addition, Chd7 is
expressed in the branchial arches in chick embryos (Aramaki et al., 2007). Using
morpholinos to reduce expression of Chd7 in X. laevis resulted in decreased expression
of the migratory neural crest specifiers Twist, Slug, and Sox9. This inhibited neural crest
cell migration in vivo resulting in reduced craniofacial cartilages and a decrease in the
distance between the eyes (Bajpai et al., 2010). Deletion of Chd7 in migrating neural
crest cells in mice also resulted in reduced craniofacial cartilages, including reductions
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in the ethmoid bones, and a decrease in the intercanthal distance. Further, the Chd7
knockout mice exhibited palatal shelf hypoplasia resulting in some mice with complete
clefting of the palate (Sperry et al., 2014). These results are similar to some of those
observed in Chd1 morphants. Specifically, the decreased intercanthal distance and
reductions in the craniofacial cartilages. Further, the ethmoid cartilage was missing in
many Chd1 morphants similar to the hypoplastic ethmoids bones in Chd7 conditional
knockout mice. Chd8 mutations are associated with a subtype of autism with features
including macrocephaly, wide-set eyes, broad nose, and pointed chin (Bernier et al.,
2014). Chd8+/- mice also display macrocephaly (Platt et al., 2017). Together, these
results demonstrate the importance of CHD family members in craniofacial
development. Therefore, the role of Chd1 was examined further to better understand
the changes that occur with reduced Chd1 expression.

Chd1 is required for neural crest and cartilage development

Craniofacial defects can occur when the development of the underlying
structures are disrupted, and often, these defects arise from problems with neural crest
development. Cranial neural crest cells migrate into the face to form cartilage, bone,
peripheral nerves, and connective tissues (Betancur et al., 2010). In addition, neural
crest cells have inductive roles in the development of other tissues, such as the head
muscle and skin (Rinon et al., 2007; Simoes-Costa and Bronner, 2015). This raised the
question of whether Chd1 deficiency results in craniofacial defects due to the disruption
of neural crest development. The spatial localization of Chd1 did indeed support a role
in the development of neural crest cells. Chd1 was present in regions behind the eye
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that were consistent with the timing and location of migrating neural crest cells. Later,
Chd1 was expressed in the branchial arches and midface regions consistent with the
locations of neural crest cells after their migration is complete. Additionally, in Chd1
morphants, expression of the neural crest regulatory gene, Ap2, was decreased, and
dying cells were localized in regions consistent with neural crest. Further, the
craniofacial cartilage, a derivative of neural crest cells, was reduced. Together, these
results indeed point to a role for Chd1 in neural crest development.
Neural crest specification and migration seem to be very susceptible to defects
when epigenetic regulators are perturbed. For instance, loss of the histone demethylase
JmjD2A results in the downregulation of expression of neural crest specifier genes
including Sox10, Sox8, FoxD3, Snail2, and Wnt1. JmjD2A acts by removing the
repressive H3K9me3 mark at the appropriate developmental time for the specification of
neural crest cells (Strobl-Mazzulla et al., 2010). HDAC repressive complexes also play a
role in regulating neural crest development. Knockdown of Hdac4 with morpholinos in
zebrafish results in the disruption of migration of cranial neural crest cells labeled with a
sox10:EGFP transgene. This disruption occurred in a subset of cranial neural crest cells
that contribute to the development of the medial ethmoid plate. This resulted in the loss
of cartilage from the ethmoid plate and clefting in the palatal skeleton (DeLaurier et al.,
2012). Hdac8 is also important for cranial neural crest development. The deletion of
Hdac8 from neural crest derived tissues resulted in defects in the development of the
frontal and interparietal bones in mice. This was similar to global deletion of Hdac8.
Loss of Hdac8 leads to the upregulation of homeobox genes such as Lhx1 and Otx2
that would normally be repressed in cranial neural crest cells, resulting in the disruption
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of skull patterning and formation (Haberland et al., 2009a; Haberland et al., 2009b). Hox
gene expression and craniofacial osteochondrogenesis is also influenced by Ezh2, a
component of the polycomb repressive complex 2. Knockout of Ezh2 in pre-migratory
neural crest cells in mice leads to severe craniofacial defects including missing jaw and
nasofrontal plate structures. These phenotypes arose from the impaired differentiation
of neural crest derived cartilage and bone. This was due to the upregulation of hox
genes in derivatives of cranial neural crest cells in Ezh2 mutant mice (Schwarz et al.,
2014). Similarly, Ring1b/Rnf2, a component of the polycomb repressive complex 1 is
also required for chondrocyte differentiation of cranial neural crest cells. In zebrafish
ring1b/rnf2 mutants, almost all of the craniofacial cartilages, including the jaw cartilages,
and craniofacial muscles are missing (van der Velden et al., 2013). Since Chd1 is also
required for epigenetic regulation of transcription, it is not unexpected that it also
regulates neural crest development.
Neural crest contribute to the development of a diverse range of derivatives
including the craniofacial bone and cartilage. The craniofacial skeleton provides the
underlying structure to form the size and shape of the face. Examination of the
craniofacial cartilages in Chd1 morphants revealed that there were reduced and missing
cartilages. These changes may be due in part to defects in neural crest development. In
addition, the expression of Has2 was also reduced in Chd1 morphants. Has2
synthesizes hyaluronan, which is a structural component of cartilage, skin, smooth
muscle, and other connective tissues (Spicer and Tien, 2004). Knockout of Has2 in
mice results in embryonic death at midgestation (E9.5-10), thus establishing that Has2
is critical for development (Camenisch et al., 2000). Has2 is expressed in areas of
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migrating neural crest and in craniofacial structures such as the developing lower jaw,
including the Meckel’s cartilage, and in the ascending palatal shelf in mice (Tien and
Spicer, 2005). In X. laevis, Has2 morphants have reduced and missing cartilages. Such
changes occurred in the palatoquadrate, Meckel’s, and ceratohyal cartilages (Casini et
al., 2012). These cartilages were also missing or reduced in Chd1 morphants,
suggesting that the changes in the facial cartilages in Chd1 morphants may be due to
the reduced expression of Has2. In addition, Has2 is necessary for the migration and
survival of pre-chondrogenic cranial neural crest cells in X. laevis. In Has2 morphants,
migration of cranial neural crest cells is impaired and there is an increase in the number
of apoptotic cells in branchial arches where neural crest cells will differentiate into
chondrocytes (Casini et al., 2012). Similarly, there was also an increase in apoptotic
cells in the area of the branchial arches in Chd1 morphants. In summary, Chd1 is
required for proper development of neural crest cells and the craniofacial cartilages, and
defects in these tissues could account for the craniofacial defects in Chd1 morphants.

Reduced Chd1 expression does not affect cell division

In addition to neural crest defects, the small size of the face of Chd1 morphants
could also be explained by decreased cell proliferation. The cell cycle was examined in
detail in the craniofacial cells using flow cytometry. These results indicate only a small
change in the mitotic phase consistent with no dramatic change in phospho-histone H3
labeling, which is associated with chromatin condensation of cells entering into the
mitotic phase (Hendzel et al., 1997). In the mouse E5.5 Chd1-/- epiblast, phosphohistone H3 labeling was about 40% higher than in control embryos. This was observed
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in combination with no significant changes in the proportion of cells in S phase,
suggesting problems with the completion of mitosis in Chd1-/- embryos (Guzman-Ayala
et al., 2015). The difference between phospho-histone H3 labeling between Chd1-/mouse embryos and X. laevis Chd1 morphants may be due to the complete knockout of
Chd1 in mice versus knockdown of Chd1 in X. laevis. Further, the difference may arise
from the difference in timing in which these embryos were examined. The Chd1-/- mice
embryos were examined prior to the onset of gastrulation, while the Chd1 morphants
were examined later in development during a time when the face is forming.
There was a minor decrease in the proportion of cells in the G0/G1 phase.
During the G1 phase, transcription and translation occurs, and cells in the G1 phase
can respond to differentiation signals and initiate cell fate decisions more quickly than
other phases of the cell cycle (Dalton, 2015; Deniz et al., 2016). Chromatin remodelers,
such as CHD family members, are involved in transcriptional regulation, both as
activators and repressors, and perhaps, Chd1 is necessary for transcriptional regulation
during G1. Since RNA synthesis is high during G1, the decrease in the proportion of
cells in G0/G1 in Chd1 morphants may be one of the contributing factor that led to the
decrease in expression of some genes observed in morphant embryos.
Additionally, Chd1 may be necessary for recognition of DNA replication origins.
The replication origins are selected during G1 and selection of origins that will be
activated is influenced by cell fate and environmental conditions (Mechali, 2010; Wu
and Gilbert, 1996). DNA replication origins are typically found in open chromatin
structures (Audit et al., 2009; Cayrou et al., 2010; Field et al., 2008; Zhou et al., 2005)
and positioning of a nucleosome at a DNA replication origin can inhibit initiation of
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replication at that origin (Simpson, 1990). During G1, the minichromosome maintenance
complex is recruited to the origin recognition complex by CDC6 and CDT1 to form the
pre-replication complex (Alabert and Groth, 2012). The assembly of this complex occurs
in the absence of a repressive chromatin structure. Histone acetylation plays a role in
facilitating an open chromatin structure (DePamphilis, 2016; Miotto and Struhl, 2010)
and perhaps, Chd1 has a role in facilitating an open chromatin structure as well.

Chd1 loss increases cell death

Most significantly, there was an increase in the proportion of cells in the sub-G1
fraction. This fraction contains cells that have lost some of their DNA, which happens
primarily when cells are undergoing apoptosis. These results suggested that there may
be increased cell death in Chd1 morphants. This was consistent with the increase in the
number of cleaved caspase 3 positive cells in Chd1 morphants. Cleavage of caspase 3
activates this proteolytic enzyme to cleave other key proteins involved in apoptosis. It
does this by activating proteins that promote apoptosis or inactivating proteins that
would inhibit apoptosis. Once apoptosis is initiated, the cell will undergo changes
including the fragmentation of DNA (Elmore, 2007). Similarly, increased apoptotic cells
have been observed in Chd1-/- mice prior to embryonic arrest (Guzman-Ayala et al.,
2015). These apoptotic cells in mice were marked by cleaved poly (ADP-ribose)
polymerase (PARP). PARP is cleaved by proteases, such as caspases, and the 24 kD
cleaved fragment binds to nicked DNA irreversibly, thus, preventing DNA repair
(Chaitanya et al., 2010).
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Chd1 has a role in DNA repair of DNA double strand breaks via homologous
recombination. Chd1 is recruited to chromatin in response to double strand break
induction, where it facilitates opening the chromatin around the double strand break.
Further, Chd1 is involved in CtIP recruitment to double strand break sites. CtIP works
with MRE11 to initiate end resection. This indicated that Chd1 plays a role in end
resection during homologous recombination mediated double strand break repair (Kari
et al., 2016).
Cleaved caspase 3 positive cells are localized to regions of neural crest
migration, providing some evidence that at least a subset of the dying cells could be
neural crest cells. Double labeling these cells with a cleaved caspase 3 marker and a
neural crest marker will be necessary to confirm this hypothesis. Taken together, the
facial abnormalities in Chd1 morphants are likely to be partially due to increased cell
death affecting the neural crest.
Chd1 has multiple roles in orofacial development. First, Chd1 is required for
expression of important neural crest and cartilage genes that are necessary for proper
development of the face. Second, Chd1 is required to maintain cells in G1 to facilitate
transcription of genes that are required at high levels. Third, Chd1 is necessary for
proper DNA repair and decreased Chd1 expression can lead to increased apoptosis as
a result of errors in repair. As a result, neural crest cells die and many of the facial
cartilages do not form properly, and consequently, this results in a smaller face (Fig
1.15).
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Chd1 cooperates with retinoic acid to regulate orofacial development

Evidence from this work and other performed in the Dickinson lab provide
overwhelming evidence that Chd1 cooperates with retinoic acid in orofacial
development. First, Chd1 expression was decreased in orofacial tissues exposed to a
RAR inhibitor during a specific time window of orofacial development. This suggested
that retinoic acid may play a role in regulating expression of Chd1. Secondly, Chd1 and
RAR𝛄 expression patterns are similar and both are expressed in craniofacial tissues
consistent with neural crest. Retinoic acid is known to be important for neural crest
development and the localization of Chd1 suggests that it too may be important for
neural crest development. Third, Chd1 morphants and embryos exposed to RAR
antagonists have similar craniofacial defects, such as a reduction in facial size
suggestive of midface hypoplasia. Further analysis utilizing morphometrics revealed that
a subset of facial landmarks change in a similar way in Chd1 morphants and embryos
exposed to a RAR inhibitor. The development of similar cartilages was altered in
response to decreased Chd1 expression or decreased RAR function, which may
account for the changes in the size and shape of the face. These changes may have
arisen from the misexpression of the neural crest and cartilage genes Ap2 and Has2
that occurs in Chd1 morphants and embryos exposed to a RAR inhibitor. Together,
these results may indicate that retinoic acid and Chd1 cooperate to regulate orofacial
development.
Another CHD family member, Chd7, also cooperates with retinoic acid to direct
neural stem cell and inner ear development. Chd7 is required to maintain the
subventricular zone stem cell niche and the rostral migratory stream. Decreased Chd7
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leads to defects in proliferation, self-renewal, and neurogenesis in neural stem and
progenitor cells in the subventricular zone. Nestin-lineage Chd7-deficient neurospheres
that were exposed to retinoic acid showed increased neuronal potential. In addition, the
inhibition of retinoic acid with citral could partially rescue the defects in the semicircular
canals in Chd7 deficient mice. Further analysis revealed that Chd7 binds directly to
Rarβ, Rxrγ, and Neurod1, suggesting that Chd7 regulates retinoic acid signaling and
pro-neuronal genes to promote proper development of the inner ear and differentiation
of neuroblasts (Micucci et al., 2014). In addition to CHD proteins, retinoic acid is known
to cooperate with other epigenetic factors. In Xenopus, the histone reader Rai1 is
regulated by retinoic acid in craniofacial development. Decreased Rai1 expression
alters facial size and shape, and leads to reductions in the ethmoid, infrarostral,
Meckel’s, and ceratohyal cartilages, which is similar to cartilages that were affected by
decreased Chd1. Further, the expression pattern of Ap2 was abnormal in Rai1
morphants (Tahir et al., 2014).
Exposure to a RAR agonist led to increased expression of Chd1 suggesting that
retinoic acid is upstream of Chd1. To assess whether retinoic acid may regulate Chd1
directly, the region upstream of the Chd1 transcription start site was examined for the
presence of RARE sites. These sites were present 5X more than expected by chance
alone. Further, these sites were found in the same regions of the Chd1 promoter in
humans, mice, and zebrafish, and at similar density to other genes known to be direct
targets of retinoic acid. Many RAREs occur as direct repeats of the core hexameric
sequence separated by 1, 2, or 5 base pairs and when this was applied as a more
stringent analysis, it revealed that none of the RARE sites in the region upstream of
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Chd1 were consistent with this pattern. Although, one site located about 600 base pairs
upstream (5’-GGGTCAcTGACCT-3’) contained a consensus sequence and a sequence
that while not a direct repeat, was one that has been shown to be part of a site bound
by RAR-RXR heterodimers in CrabpII in mice (Durand et al., 1992). These two
sequences were separated by 1 base pair and may represent a potentially functional
site that may be bound by a RAR-RXR heterodimer. Further analysis with an alternative
consensus sequence, 5’-(A/G)G(G/T)T(G/C)A-3’ (Lalevee et al., 2011), revealed the
presence of one RARE site that consisted of a repeat spaced 5 base pairs apart located
6212 base pairs upstream of the Chd1 transcription start site. In addition, ChIP-seq
experiments have identified many loci in which RAR binding occurred at a half site with
no identifiable direct repeat (Delacroix et al., 2010), suggesting the potential that a direct
repeat may not be necessary for RAR to bind to Chd1. Unfortunately, the cryptic nature
of RAREs present limitations for bioinformatic analysis. An example of this is the F11r
promotor. ChIP experiments identified a region of the F11r promoter that was bound by
RARγ and thought to contain a RARE. However, deletion reporter construct analysis
revealed that this RARE site was not necessary for retinoic acid induced expression, but
a different sequence was necessary, and bioinformatic analysis did not identify a RARE
site in this sequence (Savory et al., 2014). There is no evidence that RARs are bound to
the Chd1 promoter in ChIP-seq experiments in mouse embryonic fibroblasts and
embryonic stem cells (Delacroix et al., 2010). However, these are very different types of
cells and thus, ChIP experiments will be necessary in embryos to determine whether
Chd1 is directly bound by retinoic acid receptors.
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Together, these results suggest that Chd1 cooperates with retinoic acid to
regulate orofacial development. This cooperation may consist of the recruitment of
Chd1 by the retinoic acid receptors and coactivators to destabilize the nucleosome
structure of retinoic acid target genes and activate transcription. Chd1 directly binds to
methylated H3K4 (Sims et al., 2005) and retinoic acid increases H3K4me3 when it
binds to receptors (Urvalek et al., 2014). Additionally, it is possible that retinoic acid is
upstream of Chd1 and may regulate Chd1 expression directly. Alternatively, retinoic
acid may regulate Chd1 expression indirectly by directing the expression of some
unknown intermediate gene. Or retinoic acid may be necessary for Chd1 expression by
some other mechanism.
The expression of another epigenetic modifier, Hdac1, was also decreased in
response to exposure to the RAR inhibitor. Further, inhibition of HDAC with trichostatin A
resulted in embryos with narrow faces similar to Chd1 morphants. HDACs are known to
bind to receptors bound to RAREs of retinoic acid regulated genes in the absence of
retinoic acid to regulate stem cell differentiation (Urvalek and Gudas, 2014). Perhaps,
retinoic acid is necessary for expression of these regulators so that they can regulate
transcription of other genes. For instance, Has2 is a retinoic acid responding gene
(Saavalainen et al., 2005) and reduced Chd1 expression resulted in decreased Has2
expression. So it may be possible that retinoic acid regulates transcription of genes
necessary for its own function.
If this is the case and retinoic acid regulates Chd1, then Chd1 might be recruited
by coactivators to facilitate transcription of retinoic acid target genes. In addition, Chd1 is
necessary for proper RNA splicing and DNA repair to ensure the accuracy of these genes
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during orofacial development. When RAR function is inhibited, Chd1 is not expressed at
sufficient levels to facilitate transcription. This results in the misregulation of genes
important for orofacial development, such as Ap2 and Has2. Further, reduced Chd1
expression may lead to defects in RNA splicing and DNA repair leading to abnormal
orofacial development (Fig. 1.16).
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CONCLUSIONS AND FUTURE DIRECTIONS

Understanding how the orofacial region develops is critical to develop strategies
to prevent birth defects affecting this region. The development of the orofacial region is
complex and every aspect involved in the development of this important region is not
completely understood. Chd1 was examined here for the first time to specifically
elucidate the role of this chromatin remodeler in orofacial development. The findings
presented in this chapter suggest that Chd1 is important for neural crest and cartilage
development in X. laevis craniofacial development. Further, this chapter presents
evidence that there may be cooperation between Chd1 and retinoic acid signaling to
regulate orofacial development. These results only scratch the surface of the
importance of Chd1 in orofacial development and potential cooperation with retinoic
acid.
An expression analysis of the orofacial tissues of Chd1 morphants would provide
insight into which genes are regulated in part by Chd1. A microarray or RNA-seq
analysis could be used to examine the orofacial tissues of Chd1 morphants at stage 2930 (35-37.5 hpf) to obtain a global view of the genes altered in response to reduced
Chd1 expression. Additionally, these results could be compared to the results from the
expression analysis of the orofacial tissues of embryos exposed to the RAR inhibitor.
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This comparison may reveal genes that are altered similarly when either Chd1
expression is reduced or RAR function is inhibited, and this may provide further support
for the possibility that Chd1 and retinoic acid are in a common pathway if many genes
are similarly altered. In addition, Chd1 is important for regulating RNA splicing and
RNA-seq analysis could also reveal whether that are alterations in gene splicing in
Chd1 morphants by aligning the sequencing results to determine if Chd1 morphants
display defects that are not observed in the sequencing results from control embryos.
The results from this study suggested that Chd1 may be important for neural
crest development, however, it is not known specifically what role Chd1 plays during
neural crest cell development. This role could be elucidated with RNA in situ
hybridization by utilizing neural crest cell specification and migration markers to
determine if expression of these markers is altered in response to reduced Chd1
expression. This analysis could be performed on embryos injected in 1 cell of the 2-cell
stage with Chd1-MO or an equal amount of control morpholino. The expression pattern
of Sox9, Twist, and Slug at the neurula stage would reveal whether Chd1 was important
for neural crest cell specification based on how these specification markers were
expressed on the Chd1 morphant side versus the control side of the injected embryo.
Further, the expression of Ap2 in embryos injected in 1 cell of the 2-cell stage at stage
26-28 (29.5-35 hpf) would reveal whether Chd1 is important for neural crest cell
migration based on whether Ap2 labeled cells are localized to areas where neural crest
cells are known to migrate to, such as the branchial arches. Finally, to assess whether
Chd1 regulates neural crest cell differentiation, Chd1 morphants could be analyzed to
determine whether cells have differentiated into neural crest cell derivatives such as
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cartilage. Col2a1 is involved in making type II collagen that is found primarily in cartilage
and could be used as a marker to determine whether reduced Chd1 expression affects
neural crest cell differentiation into chondrocytes.
Another question that remains is whether reduced Chd1 expression leads to
downregulation of genes such as Ap2 and Has2 as a result of misregulation of
transcription or as a result of increased cell death. Therefore, the pan-caspase inhibitor,
Z-VAD-FMK, could be used to inhibit cleaved caspase mediated execution of apoptosis
in Chd1 morphants. The expression of Ap2 and Has2 could be examined with qRT-PCR
stage 29-30 (35-37.5 hpf) in the head tissues of morphant embryos to determine
whether their expression is downregulated in response to reduced Chd1 expression. If
expression of these genes is still downregulated in embryos exposed to the pancaspase inhibitor, then this would suggest that reduced expression of Chd1 results in
the misregulation of transcription of these genes. Alternatively, if expression of Ap2 and
Has2 is not altered in Chd1 morphants exposed to the pan-caspase inhibitor, then this
would suggest that it is the increase in cell death that results in reduced expression of
these genes in response to loss of Chd1.
The increase in cell death that was observed in Chd1 morphants may be the
result of defects in DNA repair in morphant embryos. Chd1 plays a role in the repair of
double strand breaks by facilitating the opening of chromatin around double strand
breaks to allow access to the DNA for repair. The presence of a phosphorylated form of
H2AX, γH2AX, generally reflects the presence of double strand DNA breaks. Therefore,
a γH2AX antibody could be utilized to determine if there is more DNA damage present
in Chd1 morphant embryos compared to controls. Immunohistological staining utilizing a

67

γH2AX antibody in embryos injected in 1 cell of the 2-cell stage with Chd1-MO or an
equal amount of control morpholino may reveal whether there are more double strand
breaks in Chd1 morphants. The presence of an increased number of double strand
breaks would suggest that there is an impairment of DNA repair.
Finally, while the results presented here support the possibility that retinoic acid
could regulate Chd1, further testing is necessary to determine if RARs bind directly to
Chd1. ChIP analysis is often used to examine the relationship between proteins and
DNA and an antibody specific to RARγ could be utilized for ChIP to determine the
regions of DNA that this protein binds to. Sequencing the DNA sequences bound to
RARγ would reveal whether Chd1 is directly bound by RARs. If the region of Chd1
bound by RARs contains a predicted RARE site, then this would strengthen the
argument that Chd1 is regulated by retinoic acid.
Together, these investigations will further reveal the role of Chd1 in orofacial
development and the importance of this chromatin remodeler in neural crest cell
development. Additionally, these experiments will provide insight into whether Chd1 is
important for regulating RNA splicing and DNA repair in the faces of Xenopus embryos
and this may provide a potential mechanism to help explain why there was an increase
in cell death in Chd1 morphants. Finally, these investigations may reveal whether Chd1
is directly bound by RARs and further our understanding of the importance of retinoic
acid signaling in orofacial development. Overall, this will enhance what is known about
how the orofacial region forms and contribute to the development of strategies to
prevent orofacial defects.
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TABLES AND FIGURES
Table 1.1: Epigenetic modifiers that are necessary for craniofacial development
Gene
Name

Gene Function

Defect in
human/animal models

Reference

OMIM
Number

Chd7

Chromatin
remodeler

CHARGE syndrome

(Basson and 608892
van
RavenswaaijArts, 2015)

Chd8

Chromatin
remodeler

Subtype of Autism

(Platt et al.,
2017)

Atrx

Chromatin
remodeler

Alpha-thalassemia
syndrome

(Gibbons and 300032
Higgs, 2000;
Ratnakumar
and Bernstein,
2013)

Wstf

Chromatin
Remodeler

Williams-Beuren
syndrome

(Lu et al.,
1998)

605681

Cfdp1

Chromatin
organization

Microcephaly (Based
on similarities with
MCPH1)

(Messina et
al., 2017)

608108

Hdac1

Histone
deacetylase

Craniofacial cartilage
defects in zebrafish

(Ignatius et al., 601241
2013)

Hdac4

Histone
deacetylase

Palatal defects and
shortened face on
zebrafish

(DeLaurier et 605314
al., 2012; Park
et al., 2006;
Williams et al.,
2010)

Brachydactyly mental
retardation syndrome in
humans
Non-syndromic oral
clefts
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610528

Hdac8

Histone
deacetylase

Cornelia De Lange
Syndrome 5
Wilson-Turner
Syndrome

(Haberland et 300269
al., 2009a;
Harakalova et
al., 2012;
Kaiser et al.,
2014)

Deletion in mice results
in loss of specific
cranial skeletal
elements
Ezh2

Subunit of
Polycomb
repressive
complex 2. PRC2
trimethylates
H3K27me3

Craniofacial bone and
cartilage defects in
mouse

(Gibson et al., 601573
2012; Schwarz
et al., 2014)

Ring1b/
Rnf2

E3 ubiquitinprotein ligase,
mediates
ubiquitination of
H2AK119

Required for
craniofacial
development in
zebrafish

(van der
608958
Velden et al.,
2013)

Rai1

Histone code
reader

Smith-Magenis
syndrome

(CarmonaMora et al.,
2010)

Weaver Syndrome

70

607642

Table 1.2: Primer sequences for qRT-PCR
Primer Name Primer Sequence
Actin-F

GGCCGTACAACTGGTATTG

Actin-R

CATGATGGCATGAGGTAAGG

Alx4-F

CAGAGTGCAGGTTTGGTT

Alx4-R

CGTAGGCAGAGGAGAAGT

Ap2-F

ACGTTGAGGACCAGAGTATC

Ap2-R

GAACACCTCGTTGGGATTG

Has2-F

GGTCTTCATGTCCCTCTACT

Has2-R

CCAACCTGCCTTGTTGAT

Lhx8-F

CTATTCCGCATACGTTCCTC

Lhx8-R

CAATGACTGGAGACCAAGAG

Msx2-F

CTCCAGGAAGCGGAAATAG

Msx2-R

CAGCCTGAATAGGAGAGTTG

Pdgfra-F

GCACAGTTCTCAGACATCAG

Pdgfra-R

GGTCTCATCCTCCCTCTTTA

Six2-F

GACGGAGAAGAGACCAGTTA

Six2-R

GTTGTGGCCGTACCATTC

Gapdh-F

ATCAAGGCCGCCATTAAG

Gapdh-R

CAAAGATGGAGGAGTGAGTG
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Table 1.3: Genes depleted in the orofacial tissues of embryos with a RAR antagonist
induced median cleft

Category
Chromatin
remodeling

Accession
Number

Gene
Name

BC094093.1 chd1

BG018373

CB943650

BU910939

chd2l

atrx

bptf

Gene
Description
Chromodomain
helicase
DNA binding
protein 1

Function
Modifies
chromatin
structure

Activate or
Repress
Transcription
Activate and
repress
(Baumgart et
al., 2017;
Kelley et al.,
1999;
Stokes et al.,
1996; Tai et
al., 2003)

ChromoModifies
domain
chromatin
helicase
structure
DNA binding
protein 2-like

Activate

Alpha
thalassemia/
mental
retardation
syndrome Xlinked

Transcription
regulation
and chromatin
remodeling

Activate

Nucleosome
remodeling
factor
subunit
BPTF-like

Histone
binding
component
of NURF

Activate
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(Siggens et
al., 2015)

(Levy et al.,
2015)

(Landry et
al., 2008)

BQ885933

Histone
chaperone

smarca2

SWI/SNF
related,
matrix
associated,
actin
dependent
regulator of
chromatin,
subfamily a,
member 2 L
homologue

Transcription
coactivator
cooperating
with nuclear
hormone
receptors

Activate
(Muchardt et
al., 1996)

BC073120.1 smarcad1 SWI/SNF
related,
matrix
associated
actin
dependent
regulator of
chromatin,
subfamily a,
containing
DEAD/H box
1

Facilitates
Repress
deacetylation
of newly
(Rowbotham
assembled
et al., 2011)
histones.
Restoration of
heterochromatin
organization
after replication

BG016780

Bromodomain
adjacent to
zinc finger
domain
protein 1Alike

Subunit of
the ATP
dependent
chromatin
assembly
factor (ACF).
Regulates
spacing of
nucleosomes

Activate

Remodeling
and spacing
factor 1

Forms
complex
with SNF2H
to remodel
and space
chromatin

Repress

BG162673

baz1a

rsf1
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(Collins et
al., 2002)

(Zhang et
al., 2017)

AF278538.1 nap1l1

BJ094806

supt6h

BC089261.1 spt16

Chromatin
organization

Histone
acetylation

BX847655

Cbx5

BC070732.1 phf20

Nucleosome
assembly
protein 1-like
1

Histone
chaperone
removes
and replaces
H2A-H2B
histone
protein dimer.
Facilitates
nucleosomal
sliding

Activate

Suppressor
of Ty 6
homologue

Histone
chaperone,
binds H3,
Enhances
elongation

Activate

FACT
complex
subunit
SPT16

Component
of the FACT
complex, a
general
chromatin
factor that
acts to
reorganize
nucleosomes

Activate

(Lee et al.,
2017)

(Endoh et
al., 2004)

(Birch et al.,
2009)

Chromobox5 Component
of heterochromatin,
recognizes
and binds
histone H3
tails methylated
at Lys-9
(H3K9me),
leading to
epigenetic
repression

Repress

PHD finger
protein 20

Activate
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Component
of the MOF
histone acetyltransferase
protein
complex.

(Bannister et
al., 2001)

(Badeaux et
al., 2012)

BG020636

Histone
deacetylation

Histone
methylation

jade2

AF020658.1 hdac1

BJ639070

CA986691

ash2l

setd8

BC100183.1 prdm2

BX850045

BP682076

nsd1

mll

E3 ubiquitin
protein
ligase Jade2

Histone
Acetyltransferase
component
of the HBO1
complex

Activate

Histone
deacetylase
1

Histone
deacetylase

Repress

Absent,
small, or
homeoticlike

Histone
methyltransferase

Activate

SET domain
containing
(lysine
methyltransferase)
8

Methyltransferase,
monomethylates
H3K20

Activate and
repress

PR domain
containing 2,
with ZNF
domain

Histone
methyltransferase,
Methylates
H3K9

Repress

Histone
lysine Nmethyltransferase,
H3 lysine-36
and H4
lysine-20
specific

histone
methyltransferase,
methylates
H3K36 and
H3K20

Activate and
repress

Myeloid/
lymphoid or
mixed
lineage
leukemia
(trithorax
homolog)

Protein
complex,
Histone
methyl
transferase,
methylates
H3K4

Activate
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(Panchenko,
2016)

(Delcuve et
al., 2012)

(Wan et al.,
2013)

(Milite et al.,
2016)

(Cheedipudi
et al., 2015)

(Huang et
al., 1998)

(Milne et al.,
2002)

Histone
BC056031.1 phf8
demethylation

Transcription
Initiation

Transcription
elongation

BP731934

taf3

BC085215.1 tceb3

CO382632

rtf1

BC108883.1 iws1

PHD finger
protein 8

Histone
lysine
demethylase

Activate

Transcription
initiation
factor TFIID
subunit 3
isoform 1

General
factor
required for
accurate and
regulated
initiation by
RNA
polymerase II

Activate

Transcription
elongation
factor B
(SIII),
polypeptide
3

Suppresses
transient
pausing of
polymerase

Activate

Rtf1,
Paf1/RNA
polymerase
II complex
component,
homologue

Component
of PAF1
complex,
Interacts
with Chd1

Activate

IWS1
homologue

Assembly
factor,
recruits
various
factors to
the RNAPII
elongation
complex
and is
recruited
via binding
to the
transcription
elongation
factor SUPT6H

Activate
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(Gu et al.,
2016; Maina
et al., 2017)

(Lauberth et
al., 2013)

(Aso et al.,
1995)

(Mayekar et
al., 2013)

(Liu et al.,
2007)

Table 1.4: Chd1 is conserved. Comparison of human Chd1 full length gene and protein
sequence and major domains with mice, frogs, zebrafish, flies, worms, and yeast.
Percent Identity with Homo sapiens
Species

Gene Protein Chromo- Chromo- Helicase DNA
domain
domain
Binding
1
2

Mus
musculus

88.10 95.84

96.00

94.44

99.52

97.38

Xenopus
laevis L

77.63 84.93

78.00

90.74

94.51

90.75

Xenopus
laevis S

78.12 85.46

80.00

90.74

93.56

91.67

Danio
rerio

70.56 79.65

86.05

90.57

92.12

87.34

Drosophila
melanogaster

53.20 49.48

57.14

48.08

74.22

48.66

Caenorhabditis
elegans

54.86 47.11

57.11

34.04

69.78

38.35

Saccharomyces
cerevisiae

50.37 38.43

56.10

28.85

54.89

30.35

77

Figure 1.1: Retinoic acid signaling. (A) Retinoic acid receptors
recruit corepressors in the absence of retinoic acid to stabilize the
nucleosome structure and repress transcription. (B) Retinoic acid
receptors recruit coactivators in the presence of retinoic acid to
destabilize the nucleosome structure and activate transcription.
TBP=TATA Binding Protein (Adapted from Niederreither and
Dolle, 2008)
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Figure 1.2: The effects of transcriptional elongation and
histone deacetylation on craniofacial development. (A)
Schematic of the experimental design for inhibitor
treatment. (B-E) Representative frontal views of faces of
stage 42-43 embryos treated with DMSO (B-C), 200uM
leflunomide (D), or 0.1uM Trichostatin A (E). (F-G) Bar
graphs representing frequency of phenotypic defect. (HI) Measurements of the intercanthal distance and face
height of treated embryos.
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Figure 1.3: Chd1 protein organization is conserved in metazoans. Schematic
representation of the Chd1 protein in human, mouse, frog, zebrafish, flies, worms, and
yeast. This shows the organization of the primary domains including the tandem
chromodomains, the helicase domain, and the DNA binding domain.
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Figure 1.4: Chd1 is expressed during early development in the head and presumptive
heart. (A) RNA isolated from whole embryos (unfertilized, 1-cell, blastula, and
gastrulation stage) or embryo heads (st. 24-25 (26-29.5 hpf), st. 29-30 (35-37.5 hpf),
st. 34-35 (44.5-53.5 hpf), and st. 40 (66-76 hpf)) was analyzed with PCR using Chd1
specific primers. (B) In situ hybridization for Chd1, lateral and frontal views. Anterior is
to the left.

81

Figure 1.5: Chd1 morpholino knockdown results in defects in the embryo. (A)
Schematic of experimental design. (B)Chd1-MO binds to the exon 2-intron 2
boundary. Deletion of exon 2 was detected with PCR using primers located in
exon 1 and exon 3 (arrows). (C) Representative lateral and frontal views of Chd1
morphants. (D) Bar graph represents the defects observed in control and Chd1
morphant embryos.
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Figure 1.6: Quantitative analysis of facial size and shape in Chd1 morphants.
(A) Facial dimensions for the intercanthal distance and face height were
measured and represented as a bar graph. (B) Landmarks for morphometric
analysis. (C) Canonical variant analysis of landmark coordinates for control
and Chd1 morphant embryos. (D) Transformation grid showing the change in
landmark positions between control and Chd1 morphant embryos.
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Figure 1.7: Chd1-MO2 knockdown results in defects in the embryo. (A) Schematic of
experimental design. (B) Chd1-MO2 binds to the translation start site. (C)
Representative lateral and frontal views of Chd1-MO2 morphants. (D) Bar graph
represents the defects observed in control and Chd1 morphant embryos.
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Figure 1.8: Knockdown of Chd1 alters gene expression, facial cartilage. (A) Schematic
of experimental design to test changes in gene expression. (B) qRT-PCR analysis of
gene expression in embryo heads reveals decreased expression of genes involved in
neural crest and cartilage development. (C) Schematic of experimental design to test
changes in cartilage development. (D) Alcian blue staining reveals missing and reduced
cartilages in Chd1 morphants. Abbreviations; Bh=Basihyal, Ch=Ceratohyal,
Eth=Ethmoid, Mk=Meckel’s, Pq=Palatoquadrate.
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Figure 1.9: Decreased Chd1 results
in an increase in cells in the sub-G1
phase.
(A)
Schematic
of
experimental design for investigating
cell cycle and cell death. (B)
Propidium iodide staining and flow
cytometry analysis reveals no
change in cell cycle, but an increase
in cells falling into the sub-G1 fraction
in Chd1 morphants. (C) Phosphohistone H3 immunohistochemistry in
control and Chd1 morphant embryo
sections shows no change in
phospho-histone H3 labeled cells.
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Figure 1.10: Decreased Chd1 results in increased cell death. (A) Experimental design
for assaying cell death in Chd1 morphants. (B) Cleaved caspase 3 IHC reveals an
increase in cell death in Chd1 morphants.
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Figure 1.11: Decreased Chd1 expression and inhibition of RAR results in
embryos with narrower faces. (A) Experimental setup for reducing Chd1
expression or inhibiting RAR. (B) Representative embryos Chd1 morphants and
embryos exposed to a RAR inhibitor. (C) Quantification of the intercanthal
distance and face height in embryos corresponding to (B). * Indicates these are
statistically different from their respective controls.
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Figure 1.12: Morphometric comparison of Chd1
morphants and embryos exposed to an RAR inhibitor.
(A) Schematic of the experimental design. (B)
Landmarks for morphometric analysis. (C) Canonical
variate analysis comparing Chd1 morphants, embryos
exposed to an RAR inhibitor, and control embryos
injected with a control MO or exposed to DMSO. (D)
Discriminate function analysis of Chd1 morphants and
embryos exposed to an RAR inhibitor shown on a
transformation grid.
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Figure 1.13: RARE sites are present upstream of the Chd1 transcription start site.
(A) Total number of RARE sites upstream of the transcription start site for chd1, fgf8,
and rai1. (B-D) Graph showing the location of enrichment of RARE sites upstream
of the transcription start site for chd1, fgf8, and rai1. (E) Schematic showing the
relative positions of RARE sites upstream of the transcription start site for chd1 in
H. sapiens, M. musculus, X. laevis, and D. rerio.
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Figure 1.14: Similarities between Chd1 and retinoic acid signaling (A) Schematic of
experiment design for examination of Chd1 expression after exposure to RAR agonist.
Bar graph summarizing qRT-PCR results reveals that Chd1 expression is upregulated
in response to 4-hour exposure to RAR agonist. (B) Chd1 and RARγ are enriched in
similar regions in the embryonic face as indicated by arrows. (C) Decreased Chd1 or
exposure to the RAR inhibitor results in reduced and missing cartilages. Ch=Ceratohyal,
Mk=Meckel’s.
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Figure 1.15: Reduced Chd1 expression results in decreased ap2 expression, an
increase in apoptosis, and reduced or missing facial cartilages.
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Figure 1.16: Chd1 cooperates with retinoic acid to regulate orofacial
development. (A) Retinoic acid regulates Chd1 expression. Chd1 is
necessary for retinoic acid receptor function. (B) Reduced retinoic acid
signaling results in decreased Chd1 expression. Reduced Chd1
expression leads to abnormal orofacial development.
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CHAPTER 2 ANALYZING THE CELL CYCLE PROFILE IN XENOPUS LAEVIS
EMBRYOS

INTRODUCTION

Flow cytometry is a powerful method to analyze cells through the use of fluorescent
agents that bind to specific molecules within the cell (See (Kruth, 1982) for review). This
method is quantitative and is capable of analyzing thousands of cells relatively quickly. It
gives an unbiased view of the cells and can identify small changes that may not be easily
identified with staining techniques. In addition, cells can be co-labeled making it possible
to examine multiple parameters of individual cells simultaneously.
In the flow cytometer, the cell suspension is injected into the center of a column of
sheath fluid. The cells are hydrodynamically focused, thus aligning the cells so that they
pass through the interrogation point, the point at which cells are exposed to the laser
source, one at a time. The pressure exerted on the sheath fluid sets the flow rate of the
cell suspension. High pressure will result in a faster flow rate and allow for quicker data
collection. However, the high pressure also increases the diameter of the core stream. If
the diameter of the core stream is much larger than the diameter of the cells, then this
increases the chances that a cell can enter the interrogation point while the previous cell
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has not fully exited the interrogation point. While it may take longer to acquire data with
lower pressure, it will reduce the diameter of the core stream. This reduces the chances
of two cells in the interrogation point at the same time and as a result, reduces the
variability of the results.
Cells in the interrogation point scatter light in all directions, and the scattered light
is detected with forward and side scatter detectors. Diffracted light is measured by the
forward scatter detector and is proportional to cell size. While refracted light is measured
by the side scatter detector and is proportional to cell granularity, or the internal
complexity of the cell. The information gathered from these two measurements can be
used to differentiate different populations of cells within the cell suspension when plotted
on a histogram. In addition, the laser source can be used to excite fluorophores bound to
cells in the interrogation to analyze specific characteristics of these labeled cells.
One such example of fluorescent labeling is the utilization of propidium iodide, a
fluorescent agent that intercalates with DNA, to investigate the cell cycle profile of cells in
a suspension. Propidium iodide has an excitation maxima of 535 nm and a fluorescent
emission maxima of 617 nm. This agent does not normally cross the membrane of live
cells and is sometimes used to differentiate live and apoptotic cells. For this reason, cells
must be permeabilized to allow propidium iodide to access DNA in the cell. One method
to do this is by fixation with agents such as alcohols, usually ethanol or methanol. These
dissolve lipids in the cell membrane. Live cells can also be labeled by incubating the cells
in a buffer containing a small amount of detergent, such as Nonidet P-40, which can
partition into the cell membrane bilayer and allow propidium iodide access into the cell.
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When labeled cells are in the interrogation point, propidium iodide is excited resulting in
the emission of fluorescence is detected by specialized filters and detectors.
The emitted fluorescence is converted into a digital signal by the electronics
component of the flow cytometer so that the gathered data can be interpreted by a
computer. A photomultiplier tube absorbs photons generated from the emission of
fluorescence and releases electrons. This signal is proportionally multiplied generating a
current that is converted into a voltage pulse. An analog-to-digital converter converts the
voltage pulse into a digital value that is transferred to the computer for data analysis.
The intensity of the fluorescence emitted by excited propidium iodide corresponds
to the DNA content in the cell. When the data acquired from these fluorescing cells is
plotted on a histogram, the result will typically show two peaks. The first peak corresponds
to cells in the G0/G1 phase and the second peak that occurs at twice the intensity of the
first peak, corresponds to cells in the G2/M phase, because the increased propidium
iodide intensity comes from cells that have doubled their DNA. The population of cells
that are represented between these two peaks on the histogram correspond to cells in S
phase. The population of cells below the first peak on the X-axis represents cells in the
Sub-G1 fraction. This phase corresponds to cells that have lost some of their DNA, which
usually happens when cells are undergoing apoptosis. Together, this data provides an
overview of the cell cycle profile of the cell population.
The protocol presented here describes a method to utilize propidium iodide
labeling and flow cytometry to examine the cell cycle profile of cells obtained from
Xenopus laevis embryos. More precisely, this method was designed to address the cell
cycle profile of cells prepared from the head tissues of these embryos, in order to examine
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the cell cycle profile that was representative of this region specifically. This method can
be applied to samples that have been exposed to chemical agents or altered with genetic
manipulation techniques to access the changes these manipulations may have on cell
proliferation relative to controls.
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METHODS

Reagents

Collagenase 2
Goat serum, 5% in 1X PBS
1X MBS
1X PBS
0.5X Ringer’s Solution (58 mM NaCl, 1.45 mM KCl, 2.5 mM HEPES, pH 7.2)
Staining buffer (100 mM Tris pH 7.5, 154 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.2%
BSA, 0.1% Nonidet P-40, 86 µg/mL RNAse A, and 20 µg/mL propidium iodide)
Trypan blue
0.25% Trypsin/EDTA

Equipment

Cell strainer, 40µm
Centrifuge, refrigerated
Eppendorf tubes, 1.5ml
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Flow cytometer
Gloves, powder free
Hemocytometer
Micropipettors, 10µl, 1000µl, with corresponding tips
Nutating rocker table
Scalpel, sterile disposable
Tubes, 1.5ml, 50ml
Water bath preset to 37°C

Collecting samples

1. Dissect the embryo heads by making two incisions through the embryo body. Make
the first cut at the posterior end of the gut to remove the pressure while making the
second cut. Make the second cut at the anterior end of the gut to completely
remove the head from the body. When the head has been dissected, transfer it to
a tube containing 1X MBS on ice using a glass pipette.

Alternatively, this method can be applied to whole embryos. Begin with step 2 and
collect the whole embryos in 0.5X Ringer’s solution.

There are a few controls that are useful when first starting with a new experiment.
(1) Include a control sample of cells only, without treatment or genetic
manipulation, and without propidium iodide to determine whether the cells will
produce a background signal in the propidium iodide channel. (2) Include a sample
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of cells only, without treatment or genetic manipulation, and with propidium iodide
to see a normal cell cycle profile. (3) Include a sample with any chemical used for
treatment or genetic manipulation only, without propidium iodide to determine
whether the addition of these will result in background signal in the propidium
iodide channel.

Dissociating tissues into individual cells

2. Remove the 1X MBS and replace with calcium free 0.5X Ringer’s solution.

The exclusion of calcium helps to prime cellular dissociation by weakening cellular
adhesion. Furthermore, the yolk is soluble in the hypotonic Ringer’s solution.

3. Use a 1000µl pipette to gently break up the tissues by pipetting them up and down.
The goal is to break up the tissues into small pieces. However, it is important that
the tissues are not treated too harshly, because that may cause cell lysis.
4. Allow the tissue pieces to settle, then remove the supernatant and replace with
fresh 0.5X Ringer’s solution.
5. Mixed the tubes on a nutating rocker table for four minutes at room temperature.
6. Repeat this process two more times allowing the tissue pieces to settle, replacing
the 0.5X Ringer’s solution and rocking for four minutes.
7. Allow the tissue pieces to settle, and then replace the 0.5X ringer’s solution with
1X PBS. Mix the tubes on a nutating rocker table for five minutes at room
temperature.
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8. Repeat this process one more time allowing the tissue pieces to settle, replacing
the 1X PBS, and rocking for five minutes.
9. Allowing the tissue pieces to settle, remove the 1X PBS and replace with 0.25%
trypsin/EDTA supplemented with 5mg/ml collagenase 2. This will dissociate the
tissues into individual cells.
10. Incubate this solution in a 37°C water bath for twenty minutes. During the
incubation, gently invert the tubes a few times every five minutes to help ensure
that the cells are dissociating. Do not mix harshly, because the cells are more
sensitive in the trypsin solution.
11. Transfer the cell suspensions using a 1000ul pipette and filter them through a
40µm cell strainer into a 50ml conical tube. This will help remove tissue pieces that
did not dissociate well.
12. Transfer the cell suspensions to 1.5ml Eppendorf tubes and centrifuge at 3000 rpm
for 2 minutes at 4°C.
13. Remove the supernatant and resuspend the cell solution in 750µl of ice cold 5%
goat serum in PBS.
14. Centrifuged the cell suspension at 3000 rpm for 2 minutes at 4°C.
15. Remove the supernatant and resuspend the cells in 50µl of 5% goat serum in PBS.
16. Remove a 10µl sample to be used for counting the cells (step 17). Add 500µl of
5% goat serum in PBS to the remaining 40µl of cell suspension and place on ice
(for use in step 18) while counting the cells.
17. Stain the cells in the 10µl sample with 30µl of trypan blue and count the cells using
a hemocytometer. Live cells will not be permeable to trypan blue and will appear
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colorless. While dead cells will take up the trypan blue stain and appear blue.
Ideally, there should not be an abundance of dead cells. If there are a lot of dead
cells, then the cells were likely treated too harshly resulting in cell lysis. To
determine the approximate number of cells in the sample follow the mathematical
calculation provided with the hemocytometer slide.
18. Centrifuge the cell suspension at 3000 rpm for 2 minutes at 4°C.
19. Remove the supernatant and resuspend the cells in staining buffer. Add 1ml of
staining buffer per 1,000,000 cells.
20. Incubate the cells in staining buffer for one hour on ice before running them on the
flow cytometer.

Analyzing the cell samples with the flow cytometer

21. Before running a sample, it is recommended that a quality control is performed
every day. This is done by mixing 350µl of 1X PBS with 1 drop of CS&T beads.
Open “Cytometer Setup and Tracking” on the computer. Load the sample and run
the bead solution on low. This will set the area scaling, laser delay, and optimal
MFI to baseline. If the flow cytometer does not pass quality control, try cleaning
and priming the flow cytometer, then repeat the quality control.
22. Prior to running the samples on the flow cytometer, filter the cell suspension
through a 40µm cell strainer. This will help to eliminate any clumps of cells that
may have formed while in the staining buffer.
23. Run sample and set flow rate. The flow rate affects the number of cells passing
through the laser at a time. The higher the flow rate, the faster the sample will run,
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and the quicker data will be collected. However, if the flow rate is too high, it may
allow more than one cell to pass through the laser at the same time. This can lead
to variability in the results. Therefore, it is often better to run the sample at a lower
flow rate to allow for more precise data collection, particularly when examining
DNA content for cell cycle analysis.
24. While the sample is running, isolate single, intact cells for your analysis by using
your cells from your control sample. To do this, create a histogram using the
software program to visualize area versus width. Adjust the voltage setting so that
the population of cells that are tightly clustered together is shown in the middle of
the histogram. Draw a gate around this population of cells. The width measurement
is proportional to cell size and this population of cells should include single cells.
Therefore, the cells that are represented higher on the X-axis compared to the
tightly clustered population correlates to cells that are bigger and likely represents
cells that occur as doublets (Fig. 2.1A). Doublets should be excluded from the
analysis because the DNA content of such cells can be interpreted incorrectly if
the flow cytometer recognizes them as one cell.
25. To further isolate single, intact cells, create a histogram to visualize side scatter
versus forward scatter. This histogram will plot the cells based on cell size, as
measured by forward scatter, and cell granularity, as measured by side scatter.
Draw a gate around the population of cells that are tightly clustered together. Cells
that are represented lower on the X- and Y-axes of the histogram compared to the
tightly clustered population of cells are dead cells and cell fragments that should
also be excluded from the analysis. Further, the cells that occur higher on the X-
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axis compared to the tightly clustered population of cells can be excluded to ensure
that doublets are being removed (Fig. 2.1B).
26. Next, create a histogram for propidium iodide and cell count.
27. Adjust the voltage so that the first peak is at 50 on the X-axis and the second peak
is at 100 on the X-axis. Use the control sample to set the voltage. Draw gates to
separate the boundaries of each phase, sub-G1, G0/G1, S, and G2/M (Fig. 2.2).
28. Set a stopping gate at 10,000 events. This will analyze 10,000 cells and then stop
collecting data so that even numbers of cells are analyzed for each sample. Before
choosing to collect data, let the sample run for a few seconds. This will allow the
peaks on the histogram to stabilize. Then choose to collect data.
29. After the first sample is finished, remove the sample tube and gently wipe off any
residual sample that may remain on the machine with a kimwipe. Load the next
sample and allow it to run for a few seconds until the peaks have stabilized. If
necessary, adjust the voltage so that the top of the first peak is in exactly the same
place with the gate as the first sample. This should only be a small change of about
1-2 units.
30. Repeat step 28 until all samples have been analyzed.

Save the settings used from the first experiment so that they can be used for future
replicates. Note that the settings used to get similar results may be slightly different
when using different flow cytometers.
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Using additional software to analyze the cell cycle profile

Software designed to analyze flow cytometry data is one alternative to using gates
to separate the boundaries of each phase of the cell cycle. Software such as FCS express
can create overlays to compare samples (Fig. 2.3A) and use models to analyze the cell
cycle profile without using gates (Fig. 2.3B). One benefit to using models to analyze the
cell cycle profile is that these models take into consideration that there is some overlap
between the phases of the cell cycle. Gates, such as those used in the example described
previously in this chapter, do not account for this potential overlap. The model used in the
example in figure 2.3 only shows percentages for G0/G1, S, and G2/M phases. Cells in
the sub-G1 fraction are included in the percent background, aggregates, and debris
(BAD) in all cycles. In the example shown, there are some cells included in the BAD
fraction of the treated sample that occur in the region of S phase. These may represent
cells that were dying before entering G2/M and were not at a point in which they would
be included in the sub G1 fraction, and therefore, not appropriately accounted for when
analyzed by using gate to separate the boundaries.
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DISCUSSION

Flow cytometry is one method that can be utilized to analyze characteristics of cells
including the cell cycle profile. While there are other methods that can be utilized to
analyze changes in cell proliferation and cell death, such as staining, flow cytometry is
quantitative and has the ability to detect small changes making it a powerful method to
examine changes in the cell cycle profile between treated and control samples. The
protocol presented here describes a method to stain live cells from X. laevis with
propidium iodide for analysis with flow cytometry. This method demonstrates that it is
possible to isolate these cells from specific tissues, as illustrated here in the head tissues
from X. laevis embryos. The ease of performing chemical genetics in X. laevis embryos
offers the potential to use the method presented here to investigate the effect of chemical
agents on the cell cycle profile.
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FIGURES

Figure 2.1: Gates will isolate cell populations for further analysis. (A) Histogram plotting
area versus width to remove doublets and cell clumps from the analysis. (B) Histogram
plotting side scatter versus forward scatter to remove dead cells and cell fragments
from the analysis.
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Figure 2.2: Examining the cell cycle profile. (A) Peak 1 and Peak 2 represent cells from
two different phases of the cell cycle. (B) Boundaries can be used to quantitate the
percentage of cells in each phase of the cell cycle.
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Figure 2.3: Analyzing the cell cycle profile with FCS Express software. (A) Overlay of
control and treated samples. Gates can be applied to the overlay to determine the
percentage of cells within each phase of the cell cycle. (B) Software includes models
that can be applied as an alternant method to analyze the cell cycle. B.A.D. = Percent
background, aggregates, and debris in all cycles.
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APPENDIX: DEVELOPING METHODS TO UNCOVER MECHANISMS REGULATED
BY CHD1

The misexpression of some genes in Chd1 morphants prompted a closer
examination of how these genes are misexpressed. Chd1-/- ESCs have lower
transcriptional output (Guzman-Ayala et al., 2015), and this raised the question of whether
transcriptional output was reduced in X. laevis Chd1 morphants. Further, Chd1 interacts
with transcriptional elongation factors including the PAF and FACT complexes (Simic et
al., 2003) and facilitates release of RNA polymerase II into productive elongation (Skene
et al., 2014). This prompted an investigation into whether transcriptional elongation was
affected in Chd1 morphants.
RNA isolated from 30 embryo heads was analyzed with qRT-PCR to examine
whether or not reduced Chd1 expression results in defects in transcriptional elongation.
Embryos were injected with 65-75ng of Chd1-MO, or an equal amount of control
morpholino at the 1-cell stage, and then raised to stage 29-30 (35-37.5 hpf). At this stage,
the heads of these embryos were dissected and collected for isolation of RNA. Next, two
sets of primers were used for qRT-PCR to determine whether there were differences in
the expression levels of the 5’ and 3’ regions of ap2, has2, and msx2. These genes were
chosen because their expression was reduced in Chd1 morphants. One set of primers
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was designed to target the 5’ end of each gene and the second set of primers was
designed to target the 3’ end of each gene. The expression levels from the 5’ primer set
were compared to the expression levels from the 3’ primer set following qRT-PCR. If the
expression levels from the 3’ primer set were different than the expression levels from the
5’ primer set in Chd1 morphants, then this would suggest that transcriptional elongation
was misregulated. Overall, there was little change between 5’ and 3’ expression of ap2,
has2, and msx2 when these were normalized to gapdh expression. This may suggest
that transcriptional elongation was not affected in the genes with decreased Chd1
expression. However, this experimental design may not have been sensitive enough to
detect if there were truly any changes.
An important factor in the design of this assay was that housekeeping gene was
not affected by loss of Chd1. Close inspection of gapdh revealed that there was very little
change in expression of this housekeeping gene in Chd1 morphants. However, if gapdh
was also affected in Chd1 morphants, then this assay would not detect changes in
transcriptional elongation when the genes were normalized to gapdh. If a suitable
housekeeping gene was not available, one alternative approach would be to use spike-in
RNAs for normalization.
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TABLES AND FIGURES

Table A.1: Primer sequences for qRT-PCR
Primer Name Primer Sequence
Ap2-F-5’

CGCAGTGCTACAGGTTATTC

Ap2-R-5’

CCGCTTCAAATCTCACAGTC

Ap2-F-3’

ACGTTGAGGACCAGAGTATC

Ap2-R-3’

GAACACCTCGTTGGGATTG

Has2-F-5’

TCTCCTTTGGACTCTATGGG

Has2-R-5’

GGTGTTCCAGAAAGGCAA

Has2-F-3’

GGTCTTCATGTCCCTCTACT

Has2-R-3’

CCAACCTGCCTTGTTGAT

Msx2-F-5’

TCCCAGGAGGATCAAAGAG

Msx2-R-5’

GAAAGGGAGGCTGGAGAT

Msx2-F-3’

CTCCAGGAAGCGGAAATAG

Msx2-R-3’

CAGCCTGAATAGGAGAGTTG

Gapdh-F-5’

GCGGCAAAGTTCAAGTCA

Gapdh-R-5’

TCTCAGCCTTAACGGTTCC

Gapdh-F-3’

ATCAAGGCCGCCATTAAG

Gapdh-R-3’

CAAAGATGGAGGAGTGAGTG
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Figure A.1: Decreased Chd1 expression
does not affect transcriptional elongation.
(A)Schematic of experimental design for
testing for defects in transcriptional
elongation. (B-D) Decreased Chd1 does
not affect transcriptional elongation of
ap2, has2, and msx2.
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